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The enzyme ATP(CTP):tRNA nucleotidyltransferase (tRNA-NT) is required for tRNA maturation and 
repair.  This enzyme adds to tRNAs the universally conserved 3’-cytidine-cytidine-adenosine (CCA) 
sequence required for aminoacylation.  Given the essential role of this enzyme in protein synthesis, 
human disease phenotypes have been linked to mutations in the gene encoding this protein 
(Aksentijevich et al. 2014; Chakraborty et al. 2014; Sasarman et al. 2015; DeLuca et al. 2016; Hull et al. 
2016; Wedatilake et al. 2016; Frans et al. 2017; Lougaris et al. 2018; Giannelou et al. 2018; Bader-
Meunier et al. 2018; Gorodetsky et al. 2018; Kumaki et al. 2019; Abdulhadi et al. 2019).  The variant 
proteins characterized to date have shown reduced thermostability relative to the native enzyme 
(Leibovitch et al. 2018, 2019), suggesting that reduced stability of tRNA-NT may lead to the phenotypes 
observed. 
 
Here, we looked at additional variant proteins to see if these disease-linked variants also show reduced 
thermostability.  The variant proteins characterized here were E43Δ which had a glutamate residue 
deleted near the N-terminus of the protein, R99W which contained an arginine-to-tryptophan 
substitution near the active site of the enzyme, and A[8] with a frame shift that truncated the protein by 
nine amino acids and altered the new C-terminal eight amino acids.   
 
Interestingly, biophysical and biochemical characterization of these variants showed no major decrease 
in thermostability relative to the native enzyme.  However, all three variants showed a reduced ability to 
incorporate AMP into a specific tRNA template in vitro.  This suggests that, in addition to reduced 
thermostability, effects in AMP incorporation may also be linked to a disease phenotype.  Interestingly, 
the E43Δ, R99W and A[8] variants all affected different aspects of AMP incorporation, reflecting their 
different locations in the protein and suggesting that AMP incorporation may be mediated by different 
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1.1 tRNA Structure, Function and Maturation 
In protein synthesis, transfer ribonucleic acids (tRNAs) serve as essential intermediaries in the 
information flow between messenger ribonucleic acids (mRNAs) and the amino acid sequence of the 
encoded proteins.  During translation, tRNAs function as adaptor molecules within the cell, “ferrying” 
specific amino acids to the ribosome where protein synthesis, defined by the mRNA transcript, occurs 
(Jakubowski 2012).  In eukaryotic cells, genes encoding tRNAs are found in the nuclear, mitochondrial 
and chloroplast genomes, and tRNAs are found in all of these locations and in the cytosol where they are 
maintained and active. 
 
In general, tRNAs consist of 70 to 85 nucleotides which typically fold into the cloverleaf-like secondary 
structure first proposed by Kim et al. (1973) (Fig. 1-1A).  Crystallographic analysis also revealed an L-
shaped tertiary structure (Kim et al. 1973), due to interactions between individual residues and the 
stacking of helical regions (Phizicky and Hopper 2010; Giegé et al. 2012) (Fig. 1-1B).  The key parts of the 
tRNA structure (Juhling et al. 2009; Giegé et al. 2012) (Fig. 1-1A) include the acceptor stem (where the 
cognate amino acid attaches), the anticodon arm (which interacts with the complementary codon in the 
mRNA), the D arm (which is recognized by appropriate aminoacyl-tRNA synthetases) (Hendrickson 
2001), the TΨC arm (with a role in stabilizing the tRNA tertiary structure by facilitating long-range 
interactions) (Chan et al. 2013), the variable loop (which may function in recognition by the appropriate 
aminoacyl-tRNA synthetase) (Wu and Gross 1993) and the discriminator base.  Importantly, the 
protruding 3’-end of the acceptor stem contains an invariant cytidine-cytidine-adenosine (CCA) 
trinucleotide sequence required for attachment of the cognate amino acid by the appropriate 
aminoacyl-tRNA synthetase (Sprinzl and Cramer 1979; Tamura and Hasegawa 1997; Jakubowski 2012).   
 
The CCA sequence is vital for an assortment of functions, including the ability of the tRNA to attach to its 
cognate amino acid, efficient export of mature tRNAs from the nucleus (Kutay et al. 1998; Arts et al. 
1998; Lipowsky et al. 1999), proper positioning of the transported amino acid in the ribosomal A site 
(Green and Noller 1997; Liu et al. 1998), assistance in peptide bond formation at the ribosomal P site 
(Kim and Green 1999; Nissen et al. 2000; Weinger et al. 2004) and reordering of water molecules leading 




Figure 1-1: Secondary and Tertiary Structure of tRNA (Wellner et al. 2018).  (A) Secondary structure 
displaying all key parts, including the discriminator base and the CCA sequence.  (B) Tertiary structure 
with diverse functions ascribed to the CCA sequence.  Shown here is the cytosolic tRNAPhe from 
Saccharomyces cerevisiae (PDB ID: 1TN1), with an equivalent colour scheme to (A). 
 
1.2 Class II tRNA Nucleotidyltransferase Function and Structure 
In eukaryotes, this 3’-CCA sequence is not encoded in the tRNA genes (Sprinzl and Cramer 1979) and is 
post-transcriptionally added to the 3’-end of the tRNA by a specialized nucleic-acid-template-
independent RNA polymerase, ATP(CTP):tRNA nucleotidyltransferase (tRNA-NT) (Deutscher 1983).  This 
enzyme belongs to the polymerase β superfamily which is characterized by an amino acid signature 
element near the N-terminus of the protein (Holm and Sander 1995) and is divided into two distinct 
groups – Class I and Class II (Yue et al. 1996; Aravind and Koonin 1999; Martin and Keller 2007).  Of note, 
in addition to catalyzing CCA addition during tRNA maturation, Class II tRNA-NTs also possess a repair 
function, where partially degraded or truncated CCA-ends are readily restored by incorporation of the 
missing nucleotides (Rosset and Monier 1963; Zhu and Deutscher 1987; Deutscher 1990; Weiner 2004).  
Furthermore, Class II tRNA-NTs also play a role in quality control of tRNAs, as those that have 
mismatching and destabilizing base-pairs at the acceptor stem undergo a second round of CCA addition, 
by which they are effectively tagged for degradation via 3’-5’ exonucleases (Wilusz et al. 2011; Kuhn et 




The resolved crystal structures of several Class II tRNA-NTs (Li et al. 2002; Augustin et al. 2003; Tomita et 
al. 2004; Toh et al. 2009) suggest a seahorse-shaped protein, which contains four domains  – designated 
head, neck, body and tail (Li et al. 2002) – that are primarily composed of α-helical elements with the 
exception of a single antiparallel β-sheet in the head domain (Fig. 1-2).  The head and neck domains of 
Class II tRNA-NTs contain five conserved motifs, designated A to E (Li et al. 2002) (Fig. 1-3).  These motifs  
 
 
Figure 1-2: Crystal Structures of Class II tRNA-NTs.  Shown are the solved Class II tRNA-NT crystal 
structures from (A) Bacillus stearothermophilus (PDB ID: 1MIV) (Li et al. 2002), (B) Aquifex aeolicus (PDB 
ID: 1VFG) (Tomita et al. 2004), (C) Thermotoga maritima (PDB ID: 3H37) (Toh et al. 2009) and (D) human 
(PDB ID: 4X4W) (Kuhn et al. 2015).  Each structure consists of α-helices (red), β-strands (yellow) and 
loops/β-turns (green).  The head, neck, body and tail domains are also labeled.  All structures are 




define the catalytic residues and nucleotide binding site (Li et al. 2002; Augustin et al. 2003; Tomita et al. 
2004; Toh et al. 2009) in the positively charged cleft in the head and neck region that serves as the  
 
 
Figure 1-3: ClustalW Alignment of Motifs A to E in the Head and Neck Domains of Class II tRNA-NTs 
(Goring et al. 2013).  Shown are the amino acid sequences of Class II tRNA-NTs from Aquifex aeolicus, 
Thermotoga maritima, Bacillus stearothermophilus, Saccharomyces cerevisiae (yeast) and human.  
Motifs A to E are boxed and labeled.  Amino acid alterations in the N-terminus, discussed in this thesis, 
are shown in green boxes.  (*) amino acid identity, (:) strongly conserved amino acid, (.) weakly 




binding region for the incoming nucleotide – cytidine triphosphate (CTP) or adenosine triphosphate 
(ATP) – and the 3’-end of the tRNA (Li et al. 2002; Tomita et al. 2004; Toh et al. 2009).  The body and tail 
domains, on the other hand, interact nearly exclusively with the sugar-phosphate backbone of the top 
half of the tRNA, namely with the acceptor stem, the D loop and the TΨC loop; while the anticodon arm 
is left exposed (Tomita et al. 2004; Xiong and Steitz 2004; Toh et al. 2009).  The tail domain, in particular, 
acts as an “anchor” for the tRNA, where it binds the TΨC loop and prevents the tRNA from “slipping” 
(Tomita et al. 2004; Betat et al. 2004; Kuhn et al. 2015) (Fig. 1-4). 
 
 
Figure 1-4: Signature Elements of the Class II tRNA-NT and Their Associated Roles (Toh et al. 2009).  In 
the T. maritima Class II tRNA-NT structure (PDB ID: 3H37), shown here as an example, the head, neck, 
body and tail domains are coloured magenta, green, cyan and orange, respectively.  Additional signature 
elements – the β-turn, flexible loop and α-helical spring – are represented by spheres (coloured blue, 





1.2.1 C-Terminal Body and Tail Domains 
While the roles of motifs A (Steitz et al. 1994; Yue et al. 1996; Steitz 1998), B (Li et al. 2002; Cho et al. 
2007), C (Li et al. 2002; Shan et al. 2008; Goring et al. 2013; Ernst et al. 2015), D (Shi et al. 1998; Yue et 
al. 1998; Li et al. 2002; Cho et al. 2007) and E (Li et al. 2002) in the N-terminal portion of the protein (Fig. 
1-3) have been well characterized over the last approximately 20 years, less is known about the body 
and tail domains of the Class II tRNA-NT due to a lack of sequence conservation in this portion of the 
protein (Betat et al. 2010). 
 
It has been shown that swapping the C-terminal region of an Escherichia coli Class II tRNA-NT with the 
corresponding region of a related poly(A) polymerase resulted in chimeric enzymes that generate 
multiple CCA triplets on tRNAs – revealing that the anchoring nature of the tail domain is directly linked 
to a single round of CCA addition (Betat et al. 2004).  The HD domain in the C-terminus of the E. coli 
Class II tRNA-NT can act as a metal-dependent phosphohydrolase, removing the 2’-3’ cyclic phosphate 
group from hydrolytically damaged tRNAs and regenerating the 3’-OH group, allowing for repair of the 
CCA-end by the same enzyme to proceed (Thompson et al. 1994; Aravind and Koonin 1998; Soukup and 
Breaker 1999; Yakunin et al. 2004; Lizano et al. 2008).   The C-terminal region of tRNA-NT can also block 
entry of tRNAs lacking a CC sequence, for the specific case of an enzyme that catalyses only addition of 
adenosine monophosphate (AMP) (Tretbar et al. 2011).  The removal of 124 amino acids from the C-
terminus of the Drosophila melanogaster tRNA-NT does not completely eliminate the activity of the 
enzyme, suggesting that the tail portion of the protein carries out its functions without interacting 
directly with the catalytic region of the enzyme (Yang 2008).  Furthermore, removal of nine amino acids 
from the C-terminus of the Arabidopsis tRNA-NT has resulted in small changes in the kinetic parameters 
(KM and kcat) of this enzyme (Leibovitch et al. 2013).  Moreover, if a green fluorescent protein is attached 
to the C-terminus of tRNA-NT, the enzyme retains activity in vivo (Leibovitch et al. 2013).  Much work 
remains to understand fully the role of the C-terminus of the tRNA-NT. 
 
1.3 TRNT1 Mutations and Diseases 
Given the central role of tRNA-NT in protein synthesis, it seems likely that this protein would be encoded 
by an essential gene and this is the case in Saccharomyces cerevisiae (Aebi et al. 1990; Giaever et al. 
2002).  Moreover, this is likely also the case in most eukaryotes, as in the majority of eukaryotic 
organisms characterized to date, there is a single gene encoding tRNA-NT (Leibovitch et al. 2013; Betat 
et al. 2015).  Previously, a temperature-sensitive (ts) mutation has been identified in the yeast CCA1 
7 
 
gene, encoding tRNA-NT (Aebi et al. 1990).  The ts defect in S. cerevisiae has been shown to be a 
hypomorphic effect, and can be overcome by overexpressing the variant protein (Goring et al. 2013).  
This observation suggests that the ts phenotype may result because the defective enzyme cannot 
generate functional tRNAs at a sufficient rate for protein synthesis at the restrictive temperature, but 
can do so at the permissive temperature (Goring et al. 2013).  Based on these observations and given 
the essentiality of tRNA-NT, it seemed reasonable that partial loss-of-function (LOF) mutations may be 
found in other organisms. 
 
This has proven to be the case, as a number of these LOF mutations have been found in the TRNT1 gene 
encoding human tRNA-NT (TRNT1).  This enzyme has been shown to be required for the maturation of 
both human cytosolic and mitochondrial tRNAs (Lizano et al. 2008).  Partial LOF mutations have been 
found in, to date, 27 patients presenting a wide range of phenotypes with differing clinical severities 
(Aksentijevich et al. 2014; Chakraborty et al. 2014; Sasarman et al. 2015; DeLuca et al. 2016; Hull et al. 
2016; Wedatilake et al. 2016; Frans et al. 2017; Lougaris et al. 2018; Giannelou et al. 2018; Bader-
Meunier et al. 2018; Gorodetsky et al. 2018; Kumaki et al. 2019; Abdulhadi et al. 2019).  These 
mutations encompass various combinations of missense mutations, nonsense mutations, deletions, 
frame shifts and splicing mutations (Table 1-1).  Thus far, there have been eighteen, one, one, four and 
five of these types of mutations, respectively, reported alone or in combination in patients. 
 
Table 1-1: Genotypes and Manifestations of Known TRNT1 Mutations 
 Genotype(s) Symptom(s) Manifested 
E43Δ 
Compound heterozygous with 
c.1246A[6] (DeLuca et al. 2016) 
o Retinitis pigmentosa with erythrocytic microcytosis 
and anisocytosis with mild anemia (DeLuca et al. 
2016) 
R99W 
Compound heterozygous with 
D163V (Aksentijevich et al. 2014) 
 
Compound heterozygous with 
R412X (Kumaki et al. 2019) 
 
Homozygous recessive (Hull et al. 
2016; Frans et al. 2017) 
o Anemia, fever, gastrointestinal symptoms, B-cell 
immunodeficiency, autoinflammation 
(Aksentijevich et al. 2014) 
o Atypical SIFD
a
 (B-cell deficiency, periodic fever and 
developmental delay without sideroblastic anemia), 
iron deficiency anemia, leukopenia and 
thrombocytopenia, cataracts, pneumonia, partial 
albinism, short stature, abnormal gonadal 
development (Kumaki et al. 2019) 
o Childhood cataract, inner retinal dysfunction, 
immunodeficiency, hypogammaglobulinemia, short 
stature with microcephaly, poor balance, 
sensorineural hearing loss, primary ovarian failure 
(Hull et al. 2016) 
o Progressive B-cell immunodeficiency, bilateral 
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congenital cataracts, dysmorphic features, 
inflammatory bowel disease, psychomotor 
retardation, severe dermatitis, bilateral 
sensorineural hearing loss, Crohn's disease (Frans et 
al. 2017) 
K107R 
Compound heterozygous with 
frame shift mutation 
o n / a 
T110I 
Compound heterozygous with 
D128G (Giannelou et al. 2018) 
o Sideroblastic anemia, fever, hereditary 
pyropoikilocytosis, hypogammaglobulinemia, 
common variable immunodeficiency, combined B- 
and T-cell immunodeficiency, mild developmental 
delay, attention deficit disorder, nausea, vomiting, 
diarrhea, hepatosplenomegaly, nodular 
regenerative hyperplasia and hemosiderosis, 
retinitis pigmentosa, decreased night time vision, 
hyperopic astigmatism, asymmetric erythema and 
swelling of digits of the hands and feet, septal 
panniculitis, superficial and deep lymphocytic 
dermatitis, asthma, recurrent otitis media, upper 
respiratory infections, sinusitis, pneumonia, 
undetermined hypercoagulable syndrome, deep 
venous thrombosis (Giannelou et al. 2018) 
D128G 
Compound heterozygous with 
T110I (Giannelou et al. 2018) 
 
Compound heterozygous with 
Y173F (Sasarman et al. 2015) 
o Sideroblastic anemia, fever, hereditary 
pyropoikilocytosis, hypogammaglobulinemia, 
common variable immunodeficiency, combined B- 
and T-cell immunodeficiency, mild developmental 
delay, attention deficit disorder, nausea, vomiting, 
diarrhea, hepatosplenomegaly, nodular 
regenerative hyperplasia and hemosiderosis, 
retinitis pigmentosa, decreased night time vision, 
hyperopic astigmatism, asymmetric erythema and 
swelling of digits of the hands and feet, septal 
panniculitis, superficial and deep lymphocytic 
dermatitis, asthma, recurrent otitis media, upper 
respiratory infections, sinusitis, pneumonia, 
undetermined hypercoagulable syndrome, deep 
venous thrombosis (Giannelou et al. 2018) 
o Gait ataxia, dysarthria, gross motor regression, 
hypotonia, ptosis, horizontal ophthalmoplegia, 
abnormal signals in brainstem and dentate nucleus 
(Sasarman et al. 2015) 
A148V 
Homozygous recessive 
(Sasarman et al. 2015) 
o Acute lactic acidosis, severe developmental delay, 
hypotonia, microcephaly, seizures, central apnea, 
progressive cortical atrophy, neurosensorial 
deafness, sideroblastic anemia, renal Fanconi 
syndrome, fever (Sasarman et al. 2015) 
T154I 
Compound heterozygous with 
L166S and c.608+1G>T 
(Chakraborty et al. 2014) 
o SIFD 
a
 (Chakraborty et al. 2014) 
I155T 
Compound heterozygous with 
R203K (Lougaris et al. 2018) 
o Fever, recurrent infections, respiratory and 




developmental delay, microcytic/sideroblastic 
anemia, combined B- and T-cell defects (Lougaris et 
al. 2018) 
M158V 
Compound heterozygous with 
I326T (Chakraborty et al. 2014) 
o SIFD 
a
 (Chakraborty et al. 2014) 
D163V 
Compound heterozygous with 
R99W and I223T (Aksentijevich 
et al. 2014) 
o Anemia, fever, gastrointestinal symptoms, B-cell 
immunodeficiency, autoinflammation 
(Aksentijevich et al. 2014) 
L166S 
Compound heterozygous with 
T154I (Chakraborty et al. 2014) 
o SIFD
a
 (Chakraborty et al. 2014) 
Y173F 
Compound heterozygous with 
D128G (Sasarman et al. 2015) 
o Gait ataxia, dysarthria, gross motor regression, 
hypotonia, ptosis, horizontal ophthalmoplegia, 
abnormal signals in brainstem and dentate nucleus 
(Sasarman et al. 2015) 
R190I 
Homozygous recessive 
(Chakraborty et al. 2014; 
Wedatilake et al. 2016) 
o SIFD
a
 (Chakraborty et al. 2014) 
o Retinitis pigmentosa, bilateral sensorineural 
deafness, hearing loss, retinopathy (Wedatilake et 
al. 2016) 
R203K 
Compound heterozygous with 
I155T (Lougaris et al. 2018) 
o Fever, recurrent infections, respiratory and 
gastrointestinal symptoms, hypertrophic 
cardiomyopathy, hypogammaglobulinemia, 
developmental delay, microcytic/sideroblastic 




(Aksentijevich et al. 2014) 
o Anemia, fever, gastrointestinal symptoms, B-cell 
immunodeficiency, autoinflammation 
(Aksentijevich et al. 2014) 
I223T 
Compound heterozygous with 
D163V (Aksentijevich et al. 2014) 
 
Compound heterozygous with 
W381fs, c.218_219ins22 and 
c.1246A[8] (Chakraborty et al. 
2014) 
 
Compound heterozygous with 
c.1057-7C>G (Chakraborty et al. 
2014; Abdulhadi et al. 2019) 
 
Compound heterozygous with 




(Chakraborty et al. 2014; 
Gorodetsky et al. 2018) 
 
o Anemia, fever, gastrointestinal symptoms, B-cell 
immunodeficiency, autoinflammation 
(Aksentijevich et al. 2014) 
o SIFD 
a
 (Chakraborty et al. 2014) 
o SIFD 
a
, skin autoimmune phenomena (lichen 
sclerosus and morphea), hypogammaglobulinemia, 
sensorineural hearing loss, retinitis pigmentosa, 
hypothyroidism, osteoporosis (Abdulhadi et al. 
2019) 
o Fever, diarrhea, vomiting, metabolic acidosis, 
electrolyte imbalance, hypogammaglobulinaemia, 
sideroblastic anaemia, encephalopathy, 
developmental delay, retinal dystrophy, progressive 
cerebellar atrophy, bacterial infections, 
gastrointestinal symptoms, dyserythropoeisis, 
central hypotonia, retinal pigmentation, 
hepatosplenomegaly, exocrine pancreatic 
insufficiency, seizures (Wedatilake et al. 2016) 
o Leigh syndrome (Gorodetsky et al. 2018) 
I326T 
Compound heterozygous with 
M158V (Chakraborty et al. 2014) 
o SIFD 
a
 (Chakraborty et al. 2014) 
G405R 
Compound heterozygous with 
c.1057-7C>G (Bader-Meunier et 
al. 2018) 
o Aseptic panniculitis associated with inherited 
immunodeficiency, fever, failure to thrive, 
septicemias, aseptic febrile manifestations, lobular 
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and septal neutrophilic panniculitis, chronic 
microcytic anemia (Bader-Meunier et al. 2018) 
R412X 
Compound heterozygous with 
R99W (Kumaki et al. 2019) 
o Atypical SIFD 
a
 (B-cell deficiency, periodic fever and 
developmental delay without sideroblastic anemia), 
iron deficiency anemia, leukopenia and 
thrombocytopenia, cataracts, pneumonia, partial 
albinism, short stature, abnormal gonadal 
development (Kumaki et al. 2019) 
K416E 
Compound heterozygous with 
c.del1054_1056+10 (Chakraborty 
et al. 2014) 
 
Compound heterozygous with 




 (Chakraborty et al. 2014) 
o Fever, sideroblastic anemia, 
hypogammaglobulinemia, developmental delay, 
bilateral sensorineural hearing loss, bilateral 
cataracts, swelling of digits of the hands and knee, 
recurrent cough, rotavirus gastroenteritis 
(Giannelou et al. 2018) 
c.1246A[6] 
Compound heterozygous with 
E43Δ (DeLuca et al. 2016) 
o Retinitis pigmentosa with erythrocytic microcytosis 
and anisocytosis with anemia (DeLuca et al. 2016) 
c.1246A[8] 
Compound heterozygous with 
I223T (Chakraborty et al. 2014; 
Giannelou et al. 2018) 
 
Compound heterozygous with 
c.609-26T>C (DeLuca et al. 2016) 
 
Compound heterozygous with 
K416E (Giannelou et al. 2018) 
o SIFD
a
 (Chakraborty et al. 2014) 
o Fever, sideroblastic anemia, combined B- and T-cell 
immunodeficiency, developmental delay, protein-
losing enteropathy, feeding intolerance, pancreatic 
insufficiency, hypoglycemia, retinitis pigmentosa, 
bilateral sensorineural hearing loss, CMV viremia, 
CMV pneumonitis, Pseudomonas necrotizing 
perianal colitis (Giannelou et al. 2018) 
o Retinitis pigmentosa with erythrocytic microcytosis 
and anisocytosis with mild anemia (DeLuca et al. 
2016) 
o Fever, sideroblastic anemia, 
hypogammaglobulinemia, developmental delay, 
bilateral sensorineural hearing loss, bilateral 
cataracts, swelling of digits of the hands and knee, 
recurrent cough, rotavirus gastroenteritis 
(Giannelou et al. 2018) 
 
Note: TRNT1 mutations, emphasized in this study, are in green boxes. 
aSIFD, sideroblastic anemia associated with B-cell immunodeficiency, periodic fevers and developmental 
delay. 
 
Although congenital sideroblastic anemia associated with B-cell immunodeficiency, periodic fevers and 
developmental delay (SIFD) ranks as the most clinically severe phenotype with childhood onset, a 
multitude of other symptoms is associated with TRNT1 mutations.  These symptoms include 
sensorineural hearing loss, cardiomyopathy and central nervous system abnormalities (Wiseman et al. 
2013) (Table 1-1).  While most of these phenotypes are systemic and affect multiple organs, some are 
restricted to specific areas of the body.  One instance of the latter is retinitis pigmentosa, where 
degeneration of light-sensing photoreceptor cells gradually take place within the outer neural retina, 
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leading to progressive loss of vision (Sharma et al. 2017).  This condition is typically accompanied by 
asymptomatic erythrocytic microcytosis, anisocytosis and mild anemia.  In general, certain TRNT1 
mutations are linked to a homozygous recessive mode of inheritance, while others are associated with a 
compound heterozygous mode.  For patients with SIFD, unfortunately, many do not survive past their 
first decade of life, due to multiple systemic dysfunctions (Wiseman et al. 2013). 
 
This essential nature of tRNA-NT is underscored by the finding that small interfering RNA (siRNA) 
knockdown of TRNT1 in wild-type human fibroblasts causes cytotoxicity and apoptosis – demonstrating 
immediate lethality when TRNT1 function is reduced (Chakraborty et al. 2014).  This observation is as 
expected, given the central role of this enzyme in tRNA maturation and function.  When the amino acid 
changes resulting from these mutations are mapped onto the higher-order structure of the human 
tRNA-NT, it is, perhaps, not surprising that most map to the head and neck region of the protein where 
catalysis occurs (Fig. 1-5). 
 
Recently, in vitro characterization (Leibovitch et al. 2018, 2019) of six amino acid substitutions (T154I, 
M158V, L166S, R190I, I223T and I326T) linked to mutations found in SIFD patients (Chakraborty et al. 
2014) has shown that these amino acid substitutions reduce the stability and catalytic activity of the 
enzyme.  The T154I and M158V amino acid substitutions map to conserved motif B which contains 
residues required to discriminate against deoxyribonucleotides during substrate binding and catalysis (Li 
et al. 2002).  The L166S substitution maps to motif C, thought to function as a spring to allow 
rearrangement of the catalytic region of the protein during catalysis (Ernst et al. 2015).  The R190I 
substitution maps to motif D, which has been implicated in the specific binding of CTP and ATP 
substrates (Shi et al. 1998; Yue et al. 1998; Li et al. 2002).  The I223T substitution maps between motifs 
D and E with the latter motif potentially playing a role in tRNA binding.  The I326T substitution maps to 
the body domain, about which relatively less is known (Fig. 1-5). 
 
All six of these amino acid substitutions have resulted in TRNT1 variants with decreased thermal stability 
(Leibovitch et al. 2018, 2019).  In particular, thermal denaturation studies have revealed melting 
temperatures of these substitution variants to be 5-7°C lower than that of the native protein.  




Figure 1-5: Locations in TRNT1 Corresponding to Known TRNT1 Mutations.  Amino acid changes and 
frame shifts are indicated.  The naturally occurring amino acids are represented by stick models.  Motifs 
A, B, C, D and E are represented by ribbons coloured red, orange, yellow, green and blue, respectively.  
Mutations in purple indicate frame shifts, and only the first altered N-terminal residue of each is 
displayed in stick model.  This structure is visualized by PyMOL (v1.7.4.5) (Schrödinger 2018). 
 
non-canonical mitochondrial tRNASer(AGY) (lacking a D arm) and a mini-tRNA derivative from Bacillus 
subtilis tRNAAsp (comprising only an acceptor stem and TΨC arm) as nucleic acid substrates (Leibovitch et 
al. 2018).  In addition, the I326T variant has revealed an affinity for CTP four-fold lower than that of the 
native enzyme, and turnover numbers for nucleotide addition with a B. subtilis tRNAAsp substrate to be 






1.4 This Work 
Given the important roles of the conserved motifs in tRNA-NT function it is interesting that the amino 
acid changes in the head and neck region of the protein do not dramatically affect enzyme activity in 
vitro, but clearly do reduce the thermal stability of the protein (Leibovitch et al. 2018).  Meanwhile, the 
amino acid change in the body region only mildly affects enzyme activity (Leibovitch et al. 2019).  We 
were interested in seeing how additional amino acid alterations further from the active site would affect 
enzyme structure and function.  We suspected that, as they are far from the active site, they are not 
residues specifically involved in catalysis, but more likely would alter the structure or stability of the 
enzyme. 
 
1.4.1 Amino Acid Changes Investigated 
We looked at three mutations that mapped to different regions of the resulting protein.  The first 
mutation, a three-nucleotide deletion, resulted in the loss of a glutamate residue from the N-terminus 
of the protein (E43Δ).  This amino acid is found at position 43 in the pre-mature form of the protein 
(containing its 29-residue mitochondrial targeting signal (MTS)) and is more N-terminal than any 
domains known to be required for enzyme activity (Figs. 1-3, 1-5).  The second mutation is a missense 
mutation (cytosine being replaced by thymine) resulting in the change of the arginine residue at position 
99 to tryptophan (R99W).  The resulting amino acid substitution is between conserved motifs A and B 
and is adjacent to the single antiparallel β-sheet found in the enzyme (Figs. 1-3, 1-5).  The final mutation 
is the addition of an adenosine residue in a string of seven adenosines beginning at nucleotide 1246 
(c.1246A[8]) resulting in a frame shift such that the C-terminal 17 amino acids of the protein are 
replaced by eight different amino acids (Table 1-2, Fig. 1-5).  All three of these mutations were identified 
in human disease phenotypes, principally associated with dysfunctions of the cardiovascular, immune, 
gastrointestinal, visual and nervous systems (Aksentijevich et al. 2014; Chakraborty et al. 2014; DeLuca 
et al. 2016; Hull et al. 2016; Frans et al. 2017; Giannelou et al. 2018; Kumaki et al. 2019) (Table 1-1). 
 
Table 1-2: Carboxy-Terminal Sequences of Native and c.1246A[8] Frame Shift Variant 
Variant Amino acid sequence 
Native LREQWKKSGYQMEKDELLSYIKKT 
c.1246A[8] LREQWKKKWLPNGKR  
 
Note: The first amino acid change resulting from the frame shift is highlighted in green, positively 




In the case for the R99W variant, three young siblings (Hull et al. 2016) and one male patient (Frans et 
al. 2017) exhibit the homozygous recessive genotype, while two young unrelated girls exhibit a 
compound heterozygous R99W/D163V genotype (Aksentijevich et al. 2014) and one young boy exhibits 
a compound heterozygous R99W/R412X genotype (Kumaki et al. 2019).  For the E43Δ 
variant, one male patient exhibits the compound heterozygous E43Δ/c.1246A[6] genotype (DeLuca et al. 
2016).  Finally, for the c.1246A[8] variant, two brothers exhibit a compound heterozygous 
c.1246A[8]/c.609-26T>C genotype (DeLuca et al. 2016), one young child exhibits a compound 
heterozygous c.1246A[8]/I223T genotype (Chakraborty et al. 2014; Giannelou et al. 2018) and one 
patient exhibits a compound heterozygous c.1246A[8]/K416E genotype (Giannelou et al. 2018).  The 
young child with the c.1246A[8]/I223T genotype is confirmed to have SIFD (Chakraborty et al. 2014).  
Intriguingly, an atypical form of SIFD has been diagnosed in the case of the young boy exhibiting the 
R99W/R412X genotype, where sideroblastic anemia is conspicuously absent (Kumaki et al. 2019). 
 
1.4.2 Thesis Objectives 
The primary goal of this thesis is to perform a biophysical and biochemical analysis of the E43Δ, R99W, 
and c.1246A[8] (abbreviated as A[8]) variants of TRNT1 (Fig. 1-6) to determine if these properties are 
altered as compared to the native enzyme, and to see if these changes suggest how these mutations 
may contribute to human pathogenesis. 
 
In addition, given how they are spread far across the sequence of TRNT1, including those in the N-
terminus and C-terminus far from the active site, these amino acid alterations will be compared to the 
detailed characterization that already has been performed in vitro on the substitutions (T154I, M158V, 
L166S, R190I and I223T) mapping within or close to the active site and that mapping to the body domain 
(I326T), to see if new information on the structure or function of tRNA-NT can be determined.  
Moreover, an analysis of the R99W amino acid substitution may provide some insight into the role of 
this single antiparallel β-sheet in enzyme activity. 
 
Ultimately, a more detailed understanding of the roles of these amino acids in tRNA-NT structure and 





Figure 1-6: Locations in TRNT1 Corresponding to TRNT1 Mutations in This Study.  Amino acid changes 
resulting from mutations are shown as sticks.  Motifs A, B, C, D and E are coloured red, orange, yellow, 















2.0 MATERIALS AND METHODS 
 
2.1 Chemicals, Reagents, Enzymes, Solutions, Buffers and Growth Media 
Table S0 in Appendix (7.0) lists all chemicals, reagents and enzymes used in this study (grades and 
suppliers indicated); Table 2-1 lists all solutions, buffers and growth media used (components indicated). 
 







2.2 Construction of Expression Systems 
 
2.2.1 Generation, Propagation and Isolation of Plasmids Encoding TRNT1 Variants 
QuikChangeTM site-directed mutagenesis (modified from Agilent Technologies 2015) was used to 
generate each TRNT1 variant, using pET15b-TRNT1 (provided by Dr. Matthew Leibovitch) encoding wild-
type TRNT1 as a template and forward and reverse primers (Table 2-2).  The reaction conditions for each 
TRNT1 variant are also listed (Table 2-3). 
 
Table 2-2: Forward and Reverse Primers Used in Site-Directed Mutagenesis 
 








Table 2-3: Reaction Conditions for Site-Directed Mutagenesis 
 
aPerformed by Dr. Matthew Leibovitch; total of 25 denaturation-annealing-extension cycles. 
 
After QuikChangeTM site-directed mutagenesis, 5 µL of each reaction mixture was loaded onto a 1% 
agarose gel and electrophoresed at 110 V for 1 hour, in order to verify the presence of the amplicons.  
Restriction digestion of each reaction mixture at 37°C for 1 hour, with the enzyme DpnI, was done to 
eliminate any parental methylated pET15b-TRNT1, and was followed by ethanol precipitation (Sambrook 
et al. 1989) and resuspension of the DNA in dH2O.  Plasmids of interest were transformed into E. coli XL2 
competent cells (Ausubel et al. 1989), and single colonies were selected for growth in 10 mL volumes of 
YT liquid medium with Amp (100 µg/mL) for 16 hours with shaking at 225 rpm at 37°C.  Plasmid 
purification from each culture was performed using the GeneJET Plasmid Miniprep Kit (Thermo 
Scientific), and ethanol precipitation was repeated to further concentrate plasmids.  The sequence of 
each plasmid, encoding the desired TRNT1 variant, was confirmed via Sanger sequencing and analysis 
(McGill University and Genome Quebec Innovation Centre). 
 
2.2.2 Generation and Isolation of Run-Off Transcription Templates (Leibovitch et al. 2013) 
Templates encoding target tRNA sequences for run-off transcription of tRNAs were generated as 
follows.  Plasmids G73 and pmBsDCCA (each 35 µg) [both gifts from Dr. Alan Weiner, University of 
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Washington; originally constructed by Cho et al. (2003) and Oh and Pace (1994), respectively], encoding 
variants of the B. subtilis tRNAAsp gene, were digested by restriction enzymes at 37°C for 4 hours in order 
to produce linearized tRNAAsp templates, as described in Table 2-4. 
 
Table 2-4: Components for Run-Off Transcription Template Generation 
 
Note: “N” denotes discriminator base. 
 
After digestion, 5 µL of each reaction mixture was loaded onto a 1% agarose gel and electrophoresis was 
carried out, as described in Section 2.2.1, to verify the presence of the desired digestion products.  Next, 
phenol/ether extraction (Sambrook et al. 1989) was performed to eliminate proteins and water-
insoluble impurities, followed by ethanol precipitation, in order to isolate the desired tRNAAsp templates 
(Sambrook et al. 1989).  The final concentration of each linearized template, to be used in a run-off 
reaction, was determined by UV-visible (UV-Vis) spectroscopy using an optical density of 260 nm (OD260). 
 
2.3 Production and Purification of TRNT1 Variant Proteins 
 
2.3.1 Protein Production (modified from Leibovitch et al. 2018) 
Plasmids encoding the TRNT1 variants, from Section 2.2.1, or encoding the TRNT1 native form were 
transformed into E. coli BL21(DE3) competent cells for heterologous protein production.  E. coli cultures 
were subsequently transferred to Fernbach flasks containing 1.3 L of YT liquid growth medium with Amp 
(100 µg/mL), and incubated for an average of 2 hours with shaking at 225 rpm and 37°C, in order to 
achieve a cell density measuring 0.4 to 0.5 at OD595.  This was followed by the addition of isopropyl-β-D-
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thiogalactopyranoside (IPTG), at a final concentration of 0.25 or 0.5 mM, and further incubation for 16 
to 24 hours with shaking at 16 or 19°C in order to induce cells. 
 
2.3.2 Cell Lysis (modified from Leibovitch et al. 2018) 
Following induction, each BL21(DE3) cell culture was transferred into two JA-10 centrifuge bottles and 
centrifuged for 10 minutes at 6 400 x g at 4°C in a Beckman J2-HS Centrifuge.  After discarding the 
supernatant, 2 mL of cold Resuspension Buffer per gram of cell pellet was added, the cell mixtures were 
vortexed until homogeneous, and the cell suspensions were subsequently passed 3 to 4 times through a 
Thermo Spectronic French Pressure Cell Press at 1 000 psi.  The resulting cell lysate was transferred to a 
JA-20 bottle and centrifuged twice for 25 minutes at 39 000 x g at 4°C, with the supernatant transferred 
to a new JA-20 bottle after the initial centrifugation. 
 
2.3.3 Ni-NTA Resin Column (modified from Leibovitch et al. 2018) 
All processes described here were conducted at 4°C.  A Bio-Rad 10 cm x 1.5 cm column, packed with Ni-
NTA agarose (QIAGEN) to a height of 1 cm, was equilibrated with two bed volumes of PBS Solution (pH 
7.5) with 10% glycerol.  The supernatant (8 to 16 mL) from Section 2.3.2 was cycled through this column 
for 30 minutes at a rate of one drop per 8 to 10 seconds.  Non-specific binding to the resin was reduced 
via passage of two more bed volumes of PBS Solution (pH 7.5) with 10% glycerol, followed by two more 
bed volumes of the same containing 10 mM imidazole.  Consecutive passages of 8, 6, 6 and 6 mL of PBS 
Solution (pH 7.5) containing 50, 100, 150 and 250 mM of imidazole, respectively, were performed in 
order to elute the His-tagged variant or native protein, at a rate of 1 drop per 3 to 5 seconds in 1.5 mL 
fractions.  These fractions were kept on ice.  The column was subsequently washed of residual protein 
with 2.5 mL of 6M Gdn-HCl and, as necessary, regenerated via passage of 5 mL of a solution of 100 mM 
nickel sulfate hexahydrate and 200 mM acetic acid. 
 
2.3.4 SDS-PAGE, Non-Reducing SDS-PAGE and Native PAGE 
Small aliquots (16 µL) from selected fractions were mixed with 1X SDS-PAGE Loading Dye (Table 2-1), 
heated for 2 minutes at 100°C, cooled to room temperature and centrifuged for 30 seconds before being 
loaded into the wells of a 4 cm x 10 cm x 0.075 cm SDS-PAGE gel (modified from Simpson et al. 2009).  
Electrophoresis was conducted at room temperature at 200 V, with a 4% stacking gel and 13% resolving 
gel, until the bromophenol blue dye front reached the bottom of the gel (typically 1.5 hours).  For 
protein visualization, the gel was separated from its plates and stained with SDS-PAGE Staining Solution 
21 
 
A, SDS-PAGE Staining Solution B and SDS-PAGE Destaining Solution, with brief intervals of microwave 
heating (Wong et al. 2000).  Densitometry analysis was subsequently performed, using ImageJ (Rasband 
2018). 
 
For non-reducing SDS-PAGE (modified from Simpson et al. 2009), the same procedure as that of SDS-
PAGE was followed, however, 1X Non-Reducing SDS Loading Dye (Table 2-1) was used for sample 
mixing. 
 
For native PAGE (Simpson et al. 2009), again the same procedure as that of SDS-PAGE was followed, 
however, 1X Native PAGE Loading Dye (Table 2-1) was used instead for sample mixing and 1X Native 
PAGE Running Buffer (pH 8.3) (Table 2-1) was used for electrophoresis.  In addition, protein samples 
were not heated and all operations were performed in a 4°C environment. 
 
2.3.5 Dialysis (modified from Leibovitch et al. 2018) 
Appropriate fractions, as judged by SDS-PAGE from Section 2.3.4, were combined (totaling 7.5 mL) in a 
50-kDa-MWCO Spectra/Por 7 Dialysis Membrane (Spectrum Labs) enclosure, and dialyzed against 1 L of 
PBS Solution (pH 7.5) with 10% glycerol for 1 hour at 4°C.  This dialyzing solution was exchanged and 
dialysis was allowed to continue overnight.  For biophysical analysis, dialysis was repeated an additional 
time, and dialysis buffer did not contain glycerol.  Upon subsequent removal from the dialysis tubing, 
each variant or native protein solution was stored in 20 µL, 500 µL and 1 000 µL aliquots at -80°C, until 
further biophysical or biochemical analysis was performed. 
 
2.3.6 Protein Concentration Determination 
The concentration of each variant or native protein was determined by the Bradford assay (Bradford 
1976; Bio-Rad Laboratories 2018).  Briefly, 3 to 6 dilutions (ranging from 5-fold to 2 500-fold) of each 
variant or native protein were prepared in 800 µL volumes, to which 200 µL of Protein Assay Dye 
Reagent Concentrate was added.  After mixing and 5 minute incubations, absorbance was measured at 
595 nm (using a Shimadzu UV-260 UV-Visible Recording Spectrophotometer).  As a standard, bovine 
serum albumen (BioShop) was prepared in 1.5, 4, 7 and 10 ng/µL 800 µL aliquots, and these were, 
similarly, combined with 200 µL of reagent and measured for absorbance.  Upon establishment of a 
standard curve, concentrations of the diluted variant or native protein within the linear range of this 
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curve were determined, and the average value for the subsequent calculations of the initial 
concentration of the variant or native protein was computed. 
 
2.4 Biophysical Characterization of TRNT1 Variant Proteins 
 
2.4.1 UV-Visible Spectroscopy 
To assess the amount of RNA that co-purified with the proteins, UV-visible (UV-Vis) spectroscopy was 
performed using a Varian Cary 100 Bio UV-Visible Spectrophotometer and the “Varian Cary WinUV Scan 
Application” (v4.10(464)).  RNase-treated samples were prepared by incubation with RNase A 
(Pancreatic) (BioShop) at a final concentration of 20 ng/µL, at room temperature for one hour, prior to 
dialysis.  After centrifugation for 3 minutes at 16 000 x g at 4°C to eliminate potential protein 
precipitate, 700 µL of native or variant protein was loaded into a 1.0 cm quartz cell and scanned at 20°C 
over a range of 200 to 400 nm. 
 
2.4.2 Circular Dichroism Spectroscopy (Secondary Structure) (modified from Goring et al. 2013) 
As in Section 2.4.1, aliquots of the native or variant TRNT1 protein were dialyzed against PBS Solution 
(pH 7.5), either with or without prior RNase A treatment. 
 
To determine the secondary structure, circular dichroism (CD) was performed using a Jasco J-815 
Circular Dichroism Spectrometer.  Nitrogen flow rate through the instrument was set to 3.8 L/minute 
and the “Spectrum Measurement” application was selected from the “Jasco Spectra Manager” software 
suite (v1.54.03, Build 1).  The scanning range was set between 200 and 260 nm; additional parameters 
were configured to standard sensitivity, a continuous scanning mode, a data pitch of 0.2 nm, a response 
of 1 second, a scan speed of 20 nm/min and a bandwidth of 1 nm.  After centrifugation, as in Section 
2.4.1, to eliminate potential protein precipitate, 300 µL of native or variant protein, at a concentration 
not exceeding 200 ng/µL, was loaded into a 0.2 cm cell cuvette, and the scan was conducted such that 
data were accumulated five times at 20°C.  In the “Spectra Analysis” application (v.1.53.04, Build 1), a 
Savitzky-Golay filter set to 25% was applied to smooth out the resulting data points. 
 
2.4.3 Circular Dichroism Spectroscopy (Thermal Denaturation) (modified from Goring et al. 2013) 
As in Section 2.4.1, aliquots of the native or variant TRNT1 protein were dialyzed against PBS Solution 
(pH 7.5), either with or without prior RNase A treatment. 
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To profile thermal denaturation, a similar process as that of Section 2.4.2 was employed.  However, the 
“Variable Temperature” application was selected instead.  The scan was set to 222 nm and the 
temperature range as 20°C to 65°C; additional parameters were configured to a delay time of 30 
seconds, a slope of 30°C/hour and a data pitch of 0.1°C.  In the “Spectra Analysis” application, a Savitzky-
Golay filter set to 25% was applied to smooth out the resulting data points, and a first-order derivative 
function was extracted to determine the protein’s melting point (Tm). 
 
2.4.4 Fluorescence Spectroscopy (modified from Leibovitch et al. 2013) 
As in Section 2.4.1, aliquots of the native or variant TRNT1 protein were dialyzed against PBS Solution 
(pH 7.5), either with or without prior RNase A treatment. 
 
To determine the tertiary structure, fluorescence spectroscopy was performed using a Varian Cary 
Eclipse Fluorescence Spectrophotometer and the “Varian Cary Eclipse Scan Application” (v1.1(132)).  An 
emission wavelength range of 310 to 400 nm was set, while an excitation wavelength of either 280 or 
295 nm was selected.  Additional parameters were configured to a scan speed of medium (600 nm/min), 
a data sampling interval of 1.0 nm, excitation and emission slit widths of 5 nm and a detector voltage of 
medium (600 V).  After centrifugation, as above, to eliminate potential protein precipitate, 600 µL of 
native or variant protein, at a concentration not exceeding 200 ng/µL, was loaded into a 1.0 cm quartz 
cell, and the scan was conducted such that data were accumulated ten times (CAT scans) at 20°C.  A 
“moving average” operation was subsequently applied to smooth out the resulting data points. 
 
2.5 Biochemical Characterization of TRNT1 Variant Proteins 
 
2.5.1 Run-Off Transcription and Purification of tRNA (modified from Leibovitch et al. 2013) 
Run-off transcription from tRNAAsp-N, tRNAAsp-NC and tRNAAsp-NCC templates was performed as follows.  
To initiate each reaction, appropriate amounts of linearized template, nucleoside triphosphates, buffer, 








Table 2-5: Components for Run-Off Transcription 
 
a5 µg tRNAAsp-N, tRNAAsp-NC or tRNAAsp-NCC template required. 
 
Purification of tRNAAsp-N, tRNAAsp-NC and tRNAAsp-NCC transcripts was achieved by a series of phenol 
extractions and ethanol precipitations, as in Section 2.2.2.  After resuspending the RNA pellet in 10 µL 
dH2O and 10 µL 2X Peattie’s Loading Dye (Table 2-1), the sample was heated at 70°C for 10 minutes and 
subsequently loaded onto a 4 cm x 10 cm x 0.075 cm 7M urea, 20% polyacrylamide gel, where 
electrophoresis was performed at 230 to 260 V for 2 to 2.25 hours, until the bromophenol blue marker 
reached the bottom.  Upon exposure to X-ray film (Super RX Fujifilm) for a period of time determined by 
the equation, 
           
where T represents exposure time in seconds (s) and n represents the number of 32P half-lives elapsed, 
the position of the relevant tRNA transcript was identified using a Kodak X-OMAT 1000A Processor, and 
the corresponding gel section excised.  This excised gel fragment (typically ~100 µL as estimated based 
on gradation in an Eppendorf tube) was crushed using a spatula, and vortexed with 400 µL phenol, 360 
µL dH2O, 28 µL 7.5M ammonium acetate, 7.5 µL 0.5 mM EDTA and 4 µL 1M sodium acetate, and was left 
overnight at 4°C within a slowly rotating Eppendorf tube to allow for transcript to diffuse out of the gel 
(Rubin 1973).  After centrifugation at 16 000 x g at 4°C for 10 min, the aqueous phase was collected and 
ethanol precipitation was performed, as described previously.  The pellet containing the tRNA transcript 
was then resuspended in 110 µL dH2O.  The remaining organic phase, containing the original gel 
fragment, was subjected to additional vortexing with 360 µL dH2O, 20 µL 7.5M ammonium acetate, 7 µL 
0.5 mM EDTA and 4 µL 1M magnesium acetate, allowing for additional transcript to diffuse out 
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overnight at 4 °C.  Isolation of the aqueous phase, ethanol precipitation and dH2O resuspension were 
repeated with this solution, and the tRNA transcript was then combined with the initial sample.  The 
concentration of total tRNA transcript was determined by 32P scintillation counting using a LKB WALLAC-
1217 RackBeta liquid scintillation counter, which was calibrated with unreacted [α-32P]-labeled ATP. 
 
2.5.2 Preparation of Baker’s Yeast tRNA 
For application in standard kinetic assays, in Section 2.5.4, bakers’ yeast tRNA was prepared as follows.  
After resuspending 20 mg of crude baker’s yeast tRNA (Roche) in 360 µL dH2O and 40 µL 3M sodium 
acetate (pH 5.2), four rounds of phenol extraction and two rounds of ether extraction were performed 
in sequence, followed by ethanol precipitation.  To remove any amino acids attached to the 3’-ends of 
the tRNA, 2M Tris-HCl (pH 8) was added, vortexed and allowed to incubate for 2 hours at 37°C (modified 
from Sarin and Zamecnik 1964).  Two more rounds each of phenol and ether extractions were then 
performed, and ethanol precipitation was repeated. 
 
To remove any 3’-terminal CCA sequences, the tRNA was immediately resuspended in 280 µL dH2O, 40 
µL 100 mM MgCl2, 40 µL 1M glycine buffer (pH 9) and 3 mg of snake venom phosphodiesterase I, type VI 
(from Crotalus adamanteus), and incubated for 1 hour at 37°C (modified from Yue et al. 1998).  This was 
followed by three rounds of phenol extraction, two rounds of ether extraction and a final round of 
ethanol precipitation to eliminate the phosphodiesterase. 
 
2.5.3 Standard Activity Assays (modified from Leibovitch et al. 2013) 
A standard activity assay was set up as a series of mixtures consisting of 100 mM glycine buffer (pH 9), 6 
mM MgCl2, 1 mM ATP and/or 0.1 mM CTP, 10 ng [α-
32P]-labeled tRNAAsp-N, -NC or -NCC and dH2O, in a 
total volume of 8 µL.  After pre-heating the mixtures for 2 minutes at 37°C, nucleotide addition was 
initiated by the addition of 2 µL native or variant TRNT1 protein of varying concentrations at 37°C.  
Reactions were terminated after 2 minutes by the addition of 10 µL 2X Peattie’s Loading Dye, and the 
resulting mixtures were heated for 10 minutes at 70°C in order to linearize the tRNA transcripts, 
followed by brief cooling on ice. 
 
Samples were separated at 2 000 V for 7.5 to 8.5 hours on a 7M urea, 12% percent polyacrylamide gel 
(38 cm x 50 cm) in 1X TBE buffer, after the gel had been pre-run at 2 000 V for 1 hour.  To locate 
products of interest, the gel was placed over a GE HealthCare Storage Phosphor Screen in an Amersham 
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Biosciences Exposure Cassette.  Allowing for some error, the image on the Phosphor Screen developed 




           
where T represents exposure time in days (d) and t represents the time between synthesis of [α-32P]-
labeled ATP and the start of exposure in days (d).  The image was subsequently scanned using a GE 
Healthcare Typhoon Trio Variable Mode Imager and a Typhoon Scanner Control (v5.0) with a pixel size 
of 100 µm, and image analysis of the tRNA transcripts was conducted using the GE HealthCare 
ImageQuant TL 1D Gel Analysis program (v7.0).  This was accomplished by densitometry analysis, where 
bands corresponding to specific tRNA sizes before and after nucleotide incorporation were assessed for 
their relative intensities. 
 
2.5.4 Standard Kinetics Assays (modified from Leibovitch et al. 2013) 
A standard kinetic assay was set up as a series of mixtures containing the same components as in 
Section 2.5.3, however, all concentrations were fixed, including that of the added native or variant 
TRNT1 protein.  For each reaction, the concentration of a single substrate (ATP, CTP, tRNAAsp-NC or 
tRNAAsp-NCC) was varied, in order to determine the specific kinetic parameters for that substrate.  After 
each reaction was initiated by the addition of an appropriate amount of protein at 37°C, termination 
was achieved at each time point (10, 20 or 40 seconds) by withdrawing 10 µL of the reaction mixture 
and mixing it with 10 µL 2X Peattie’s Loading Dye, followed by heating for 10 minutes at 70°C and brief 
cooling on ice.  Each time point for each reaction was performed in duplicate or triplicate.  For kinetic 
assays of varying tRNAAsp-NC or tRNAAsp-NCC concentrations, purified baker’s yeast tRNA, as prepared in 
Section 2.5.2, was used to supplement for the higher tRNA concentrations demanded (typically above 
1.2 ng/µL). 
 
Electrophoresis of the mixtures, image exposure and analysis were conducted as described in Section 
2.5.3. 
 
Percent addition and initial velocity (vo) of each reaction corresponding to each concentration of the 
varied substrate were determined, and nonlinear regression was performed using GraFit 7 
(Leatherbarrow 2009), in order to model the resultant kinetics based on the Michaelis-Menten and Hill 
equations.  For both models, the maximum reaction rate (Vmax), apparent Michaelis constant (KM,Apparent), 
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turnover number (kcat) and specificity constant (kcat/KM,Apparent) were computed.  For the Hill model, the 
Hill coefficient (n) was also determined. 
 
2.6 Molecular Modeling and Visualization of TRNT1 Variant Proteins 
The structure of the native TRNT1 protein was based on X-ray crystallographic data downloaded from 
the RCSB Protein Data Bank (PDB ID: 4X4W; Kuhn et al. 2015).  To simulate the folded structure of each 
variant TRNT1 protein, a hybrid modeling approach called Robetta (beta version) was employed, 
combining both homology modeling and ab initio structure prediction (Kim et al. 2004), and upon 
output the top-ranking structure for each variant was selected. 
 
To simulate the tertiary structure of the B. subtilis tRNAAsp-NCCA, its sequence and corresponding 
secondary structure were downloaded from the Transfer RNA Database (Juhling et al. 2009) (tRNAdb ID: 
tdbD00000402; Yumada et al. 1983; Green et al. 1985), and the molecule was folded in silico without 
need for a structural template or sequence alignment, by RNAComposer (Popenda et al. 2012). 
 
Finally, to simulate docking of the native or variant protein with the tRNAAsp-NCCA, a hybrid algorithm of 
template-based modeling and ab initio free docking called HDOCK (Pearson and Lipman 1988; Remmert 
et al. 2012; Yan et al. 2017) was employed, and the complex with the lowest docking energy score was 
selected, given that the 3’-end of the tRNAAsp-NCCA was within close proximity to the active site. 
 
















3.1 TRNT1 Variant Protein Amounts and Purities 
Following production and purification of native, R99W, E43Δ and A[8] TRNT1 variant proteins, total 
protein amounts were determined by Bradford assay (Table S1); and SDS-PAGE (Fig. 3-1), non-reducing 
SDS-PAGE (Fig. 3-2) and native PAGE (Fig. 3-3) were carried out on aliquots of each.  (In Figs. 3-1 to 3-3, 
the gap preceding the A[8] variant reflects the removal of lanes containing samples not pertinent to this 
discussion.  For completeness, the original gel images are shown in Fig. S2.) 
 
All recombinant proteins showed sizes in the ranges of those expected (Fig. 3-1) based on the predicted 
monomer sizes of 48.5, 48.6, 48.4 and 47.5 kDa for the native, R99W, E43Δ and A[8] variant proteins, 
respectively.  For the sake of comparison, the mass of the A[8] variant was determined by mass 
spectrometry (MS) and this mass (47,360 Da) showed a good correlation with the mass determined by 
SDS-PAGE (~47.5 kDa) and the predicted mass based on the amino acid sequence (47,355 Da).  
Densitometry was performed on each SDS-PAGE sample to determine relative enzyme purity, defined as 
the relative ratio of protein of the expected molecular mass as compared to all proteins in the sample, 
and all samples showed >80% purity (Table S1, Fig. S1). 
 
 
Figure 3-1: SDS-PAGE of Variant and Native TRNT1 Proteins.  For each TRNT1 variant (and native) 
sample, 16 µL of a 100 ng/µL aliquot were loaded, followed by electrophoresis and gel staining.  
Unstained Protein Molecular Weight Marker (no. 26610) (Thermo Scientific) was used as a molecular 




3.2 Quaternary Structures of TRNT1 Variants 
In addition to SDS-PAGE, non-reducing SDS-PAGE and native PAGE of native and variant TRNT1 proteins 
were performed in order to gain insight into possible quaternary structures.  Non-reducing SDS-PAGE 
with aliquots of each native and variant protein (Fig. 3-2) showed species at ~100 kDa, suggestive of 
dimerization products for the native, R99W, E43Δ and A[8] proteins.  When native PAGE was performed 
(Fig. 3-3), all samples showed two major species, one of which migrated through the gel approximately 
half as far as the other, consistent with two forms of the native enzyme. 
 
Figure 3-2: Non-Reducing SDS-PAGE of Variant and Native TRNT1 Proteins.  For each TRNT1 variant 
(and native) sample, 8 µL of a 200 ng/µL aliquot were loaded (without β-mercaptoethanol), followed by 




Figure 3-3: Native PAGE of Variant and Native TRNT1 Proteins.  For each TRNT1 variant (and native) 
sample, 8 µL of a 200-ng/µL aliquot were loaded (without β-mercaptoethanol and SDS), followed by 
electrophoresis and gel staining.  (Molecular Weight Marker as in Figure 3-1.  No marker sizes could be 
confidently assigned.)  See Figure S2C for original gel image. 
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3.3 Biophysical Characterization of TRNT1 Variants 
 
3.3.1 Amount of Co-Purified RNA Bound 
As this protein uses RNA as a substrate and nucleic acids have an absorption maximum at 260 nm, while 
aromatic amino acids show an absorption maximum at 280 nm, a ratio of absorbance at 280 nm to that 
at 260 nm (A280:A260) was calculated for each protein, either before or after RNase treatment, to assess 
the amount of E. coli nucleic acid that co-purified with the enzyme (Fig. 3-4).  Before RNase treatment, 
the native, R99W and E43Δ proteins showed A280:A260 ratios well below one resulting from a significant 
contribution from RNA, while the A[8] variant showed a ratio greater than one.  After RNase treatment, 
all samples showed ratios between 1.34 and 1.59.  The largest change in the A280:A260 ratio upon RNase 
treatment was seen for the native enzyme (an increase of 0.94 ± 0.1), followed by the R99W variant (an 
increase of 0.71 ± 0.1) and the E43Δ variant (an increase of 0.69 ± 0.1).  In contrast, the A[8] variant 
showed only a 0.17 ± 0.8 increase, primarily as a result of a limited reduction in A260 nm as compared to 
the other samples. 
 
 
Figure 3-4: A280:A260 Ratios of Native and Variant TRNT1 Proteins.  The ratios of UV absorbance at 280 
and 260 nm are displayed for native, R99W, E43Δ and A[8] TRNT1 proteins for samples treated (red) or 
untreated (blue) with RNAse A.  The number of experimental replicates is denoted in parentheses, with 




3.3.2 Secondary Structures 
In order to assess any changes in the secondary structures of the TRNT1 variants, CD spectroscopy was 
performed on all samples before and after RNase treatment.  In either condition, the CD spectra of all 
proteins were characteristic of a mixed α-helix/β-strand structure indicative of minimal or no change in 
secondary structure from that of native TRNT1.  CD signal traces of the raw data are shown in Fig. S3A 
and Fig. S3B, while traces normalized to those of the native enzyme are shown in Fig. S3C. 
 
3.3.3 Thermal Stabilities 
In order to assess any changes in the thermal stabilities of the TRNT1 variants, thermal denaturation was 
performed by following the ellipticity of each protein at 222 nm as the temperature was raised from 20 
to 65°C in order to follow total remaining α-helical content (Fig. S4A).  Using these data, a Tm, defined as 
the temperature at which 50% of the α-helical content is unfolded (20°C is assigned 100% α-helical 
content), was calculated for each sample.  There was a difference of only 3°C or less in Tm (thermal 
stability) between all samples upon comparison either before or after RNase treatment (Fig. 3-5).  A 
decrease of ~2.5°C in Tm was observed for the native enzyme upon RNase treatment, while smaller 
decreases upon RNase treatment were seen in the other samples.  The Tm for the native enzyme was in 
excellent agreement with that determined previously (Leibovitch et al. 2018) for the native enzyme 
(42.4°C).  Thermal denaturation curves normalized to those of the native enzyme are shown in Fig. S4B, 
while fractions unfolded are shown in Fig. S4C. 
 
Figure 3-5: Melting temperatures (Tm’s) of Native and Variant TRNT1 Proteins.  Tm’s are displayed for 
native, R99W, E43Δ and A[8] TRNT1 proteins before (red) and after (blue) treatment with RNAse A.  The 
number of experimental replicates is denoted in parentheses, with error bars representing one SEM. 
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3.3.4 Tertiary Structures 
In order to assess any changes in the tertiary structures of the TRNT1 variants, fluorescence 
spectroscopy was performed.  Whether assayed for fluorescence after excitation at 280 nm or 295 nm, 
or before or after RNase treatment, emission spectrum peaks were red-shifted by only up to a maximum 
of ~4 nm for excitation at 280 nm and ~2.7 nm for excitation at 295 nm, as compared to the native 
enzyme (Fig. 3-6).  Fluorescence emission traces of the raw data are shown in Fig. S5A (without RNase) 
and Fig. S6A (with RNase), while traces normalized to those of the native enzyme are shown in Fig. S5B 
(without RNase) and Fig. S6B (with RNase). 
 
Figure 3-6: Fluorescence Emission Maxima of Native and Variant TRNT1 Proteins.  Fluorescence 
emission maxima are displayed for native, R99W, E43Δ and A[8] TRNT1 proteins.  Maxima for non-
RNase-treated aliquots after excitation at 280 and 295 nm are represented by dark and light blue bars, 
respectively, and maxima for RNase-treated aliquots after excitation at 280 and 295 nm are represented 
by yellow and red bars, respectively.  The number of experimental replicates for each maximum is 
denoted in parentheses, with error bars representing one SEM. 
 
3.4 Biochemical Characterization of TRNT1 Variants 
 
3.4.1 Activities 
To address any changes in enzyme activities of the TRNT1 variants, standard end point assays 
(Leibovitch et al. 2013) were set up in order to gauge the amount of enzyme required for AMP and/or 
CMP incorporation (A- and/or C-addition, respectively) on different tRNA transcripts.  Four separate 
experimental conditions were used – tRNAAsp-NCC and ATP (Fig. 3-7), tRNAAsp-NC and CTP (Fig. 3-8), 
tRNAAsp-N and CTP (Fig. 3-9), and tRNAAsp-N and CTP and ATP (Fig. 3-10). 
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3.4.1.1 AMP Addition to the tRNAAsp-NCC Transcript 
In the assay measuring AMP addition to the tRNAAsp-NCC transcript (Fig. 3-7), at the highest protein 
amount tested (9.2 ng), the native enzyme showed 74% final product formation.  All variant enzymes 
tested showed considerably less AMP incorporation, with 26%, 18% and 11% by the R99W, E43Δ and 
A[8] variants, respectively, at similar protein amounts.  Furthermore, a similar level of product formation 
to that of the native enzyme was observed for the A[8] variant only when its amount was increased by 
approximately 10-fold to 83.9 ng (63% product formed). 
 
 
Figure 3-7: Activity Assay of Native and Variant TRNT1 Enzymes (AMP Incorporation onto tRNAAsp-
NCC).  (A) Enzyme and amount used are indicated beneath each lane, while numbers above each lane 
indicate relative amounts of tRNAAsp-NCCA and tRNAAsp-NCC at the completion of each two-minute 





3.4.1.2 CMP Addition to the tRNAAsp-NC Transcript 
In the assay measuring CMP addition to the tRNAAsp-NC transcript (Fig. 3-8), at 3.7 ng, the native enzyme 
showed 48% final product formation, while at similar levels, 26% and 13% were seen for the E43Δ and 
A[8] variants.  A comparable level of product formation to that of the native enzyme was only attainable 
by the A[8] variant when its amount was increased by approximately 25-fold to 83.9 ng (76% product 
formed).  Surprisingly, for the R99W variant, 74% final product formation was observed at only 5 ng, 
suggesting an increased ability of this variant, as compared to the native enzyme, to incorporate CMP 
onto the tRNAAsp-NC transcript. 
 
Figure 3-8: Activity Assay of Native and Variant TRNT1 Enzymes (CMP Incorporation onto tRNAAsp-NC).  
(A) Enzyme and amount used are indicated beneath each lane, while numbers above each lane indicate 
relative amounts of tRNAAsp-NCC and tRNAAsp-NC at the completion of each two-minute reaction.  (B) 
Graphical representation of data from (A).  *: Performed by Nathalie Reid. 
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3.4.1.3 CMP Addition to the tRNAAsp-N Transcript 
In the assay measuring CMP addition to the tRNAAsp-N transcript (Fig. 3-9), all enzymes showed much 
reduced activity with tRNAAsp-NCC product formation at roughly 5% at approximately 10 ng of protein in 
nearly all cases.  The exception is the E43Δ variant, which showed 23% tRNAAsp-NCC product formation 
at this amount, suggesting an increased ability, as compared to the native enzyme, of the E43Δ variant 
to incorporate CMP onto the tRNAAsp-N transcript. 
 
Figure 3-9: Activity Assay of Native and Variant TRNT1 Enzymes (CMP Incorporation onto tRNAAsp-N).  
Enzyme and amount used are indicated beneath each lane, while numbers above each lane indicate 
relative amounts of tRNAAsp-NCC, tRNAAsp-NC and tRNAAsp-N at the completion of each two-minute 
reaction. 
 
3.4.1.4 CMP and/or AMP Addition to the tRNAAsp-N Transcript 
In the assay with tRNAAsp-N, CTP and ATP as substrates (Fig. 3-10), a similar pattern to that of the assay 
using tRNAAsp-N and CTP (Fig. 3-9) was observed.  This experiment differs from those described above, in 
that in this case both ATP and CTP can be incorporated.  Given the results shown in Fig. 3-9 for CMP 
incorporation alone, it is reasonable to assume that the addition of the first two nucleotides represents 
CMP incorporation and that of the final nucleotide represents AMP incorporation.  Here, at 9.2 ng, the 
native enzyme showed 37% tRNAAsp-NCCA product formation, while the R99W, E43Δ and A[8] variants 
showed considerably less (≤11%) at similar protein amounts (Fig. 3-10).  Again, a comparable level of 
final product formation to that of the native was observed for the A[8] variant only when its amount was 




Figure 3-10: Activity Assay of Native and Variant TRNT1 Enzymes (CMP and AMP Addition to tRNAAsp-
N).  Enzyme and amount used are indicated beneath each lane, while numbers above each lane indicate 
relative amounts of tRNAAsp-NCCA, tRNAAsp-NCC, tRNAAsp-NC and tRNAAsp-N at the completion of each 
two-minute reaction. 
 
3.4.1.5 Misincorporation of CMP and/or AMP onto tRNAAsp Transcripts By the E43Δ Variant 
Given that the E43Δ variant showed better final product formation when CMP was incorporated onto 
tRNAAsp-N than did the native enzyme (23% versus 8%, respectively, at approximately 10 ng in Fig. 3-9), 
but less final product formation when ATP was also present in the reaction (11% versus 37%, 
respectively in Fig. 3-10) or when AMP was incorporated onto tRNAAsp-NCC (18% versus 74%, 
respectively, in Fig. 3-7), a difference in the ability to incorporate CMP or AMP by the E43Δ variant was 
suggested. 
 
Therefore, the ability of the E43Δ variant to incorporate CMP onto tRNAAsp-N or tRNAAsp-NC was tested 
at higher enzyme amounts.  CMP incorporation onto the tRNAAsp-NC transcript showed run-on 
transcription with tRNAAsp-NCCC and -NC(4) products forming at 11.5 and 46.2 ng of E43Δ protein, 
respectively (Fig. 3-11A).  In comparison, the native enzyme showed a tRNAAsp-NCCC product only 
starting to form at 24.1 ng (Fig. 3-11A).  Similarly, CMP incorporation onto the tRNAAsp-N transcript 
showed tRNAAsp-NCCC, -NC(4) and -NC(5) products forming at 11.5, 46.2 and 115.4 ng of E43Δ protein, 
respectively (Fig. 3-11B).  Here, run-on C-adding activity with the E43Δ protein was seen as early as 4.6 
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ng, where a tRNAAsp-NCCC product was first evident (Fig. 3-11B), in contrast to that of the native 
enzyme, which only showed this run-on product at 96.5 ng of protein. 
 
 
Figure 3-11: Activity Assays of E43Δ Variant.  (A) CMP incorporation onto tRNAAsp-NC.  (B) CMP 
incorporation onto tRNAAsp-N.  (C) CMP and AMP incorporation onto tRNAAsp-N.  Enzyme and amount 
used are indicated beneath each lane, while numbers above each lane indicate relative amounts of 
transcript products and reactants at the completion of each two-minute reaction. 
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When both ATP and CTP were provided to the tRNAAsp-N transcript, interestingly, there was limited 
extension beyond the third (typically -NCCA) position (Fig. 3-11C), observable with E43Δ protein 
amounts of 46.2 and 115.4 ng. 
 
3.4.2 Kinetics 
Based on the data generated from the end point assays, it seemed worthwhile to define more specific 
kinetic parameters for these TRNT1 variants.  Specifically, kinetic analyses were performed to determine 
any changes in apparent Michaelis constants (KM,Apparent’s ) for nucleoside triphosphates (NTPs) or nucleic 
acids, or for turnover numbers (kcat’s), as compared to the native enzyme.  Four different experimental 
conditions were employed by altering ATP, CTP, tRNAAsp-NCC or tRNAAsp-NC concentrations (Tables 3-1, 
3-2, 3-3 and 3-4, respectively).  A subset of representative kinetic assay plots for the native enzyme is 
shown in Fig. S7. 
 
3.4.2.1 Varying ATP Concentration 
When the ATP concentration was varied and the amount of tRNAAsp-NCC transcript was fixed (Table 3-1), 
in terms of KM,Apparent for ATP binding, the E43Δ and A[8] variants showed less than a three-fold increase 
compared to that of the native enzyme, while the R99W variant showed an approximately 100-fold 
decrease compared to that of the native enzyme (1.14 ± 0.6 µM versus 124.31 ± 39.3 µM).  In terms of 
kcat, the E43Δ variant showed no real change, although it showed less product formation in the end point 
assay (Fig. 3-7).  In contrast, the R99W and A[8] variants showed a 5-fold (0.04 ± 0.0 s-1) and 10-fold 
(0.02 ± 0.0 s-1) decrease in kcat, respectively, compared to that of the native enzyme (0.17 ± 0.0 s
-1), 
which agrees well with the reduced activity seen previously in the end point assays (Fig. 3-7). 
 
3.4.2.2 Varying CTP Concentration 
When the CTP concentration was varied and the amount of tRNAAsp-NC transcript was fixed (Table 3-2), 
the R99W and E43Δ variants showed a 20-fold (0.22 ± 0.4 µM) and 3-fold (1.61 ± 0.2 µM) decrease in 
KM,Apparent, respectively, compared to that of the native enzyme (4.60 ± 0.6 µM), while the A[8] variant 
showed a 7-fold increase (32.03 ± 38.5 µM).  In comparing all variants and the native enzyme to each 
other, there was on the order of a greater than 100-fold difference in KM,Apparent values.  In contrast, 
differences in kcat values among all enzymes were three-fold or less (ranging from 0.07 ± 0.0 s
-1 for the 




Table 3-1: Kinetic Assay of Native and Variant TRNT1 Enzymes (Varying ATP and Fixed tRNAAsp-NCC) 
 
(A) Calculated values. 
(B) Calculated values from (A) normalized to those of native TRNT1. 
Note: Green, native values; red, “weaker” than native values; blue, “stronger” than native values. 
Note: The SEM is included where applicable. 
 
Table 3-2: Kinetic Assay of Native and Variant TRNT1 Enzymes (Varying CTP and Fixed tRNAAsp-NC) 
 
(A) Calculated values. 
(B) Calculated values from (A) normalized to those of native TRNT1. 
Note: Green, native values; red, “weaker” than native values; blue, “stronger” than native values. 
Note: The SEM is included where applicable. 
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3.4.2.3 Varying tRNAAsp-NCC Concentration 
When assayed using the Michaelis-Menten model of enzyme kinetics and varying the amount of 
tRNAAsp-NCC transcript (Table 3-3), the R99W variant showed an 11-fold increase in KM,Apparent as 
compared to the KM,Apparent of the native enzyme (0.14 ± 0.0 µM), while the E43Δ and A[8] variants 
showed only a two-fold decrease or increase, respectively.  In terms of kcat, the R99W, E43Δ and A[8] 
variants showed a 2-fold (2.06 ± 0.2 s-1), 6-fold (0.61 ± 0.1 s-1) and 33-fold (0.10 ± 0.0 s-1) decrease, 
respectively, as compared to that of the native enzyme (3.86 ± 0.2 s-1), again agreeing well with the 
reduced activity seen previously in the end point assays (Fig. 3-7).  Not surprisingly, kcat/KM,Apparent’s for 
tRNAAsp-NCC were lower than those of the native enzyme (20-fold, 3-fold and 100-fold lower for the 
R99W, E43Δ and A[8] variants, respectively).  Similar trends were seen when these data were fitted to 
the Hill model.  Only the R99W variant showed a Hill coefficient greater than one (n = 1.11 ± 0.0), with 
apparent 2-fold (0.31 ± 0.0 µM), 7-fold (0.59 ± 0.0 s-1) and 14-fold (1.86 ± 0.3 µM-1 s-1) differences in 
KM,Apparent, kcat or kcat/KM,Apparent, respectively.  This suggests that under these conditions, cooperativity is 
not an issue. 
 
Table 3-3: Kinetic Assay of Native and Variant TRNT1 Enzymes (Varying tRNAAsp-NCC and Fixed ATP) 
 
(A) Calculated values. 
(B) Calculated values from (A) normalized to those of native TRNT1. 
All data fitted to Michaelis-Menten model except for a which is fitted to Hill model. 
Note: Green, native values; red, “weaker” than native values; blue, “stronger” than native values. 
Note: The SEM is included where applicable. 
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3.4.2.4 Varying tRNAAsp-NC Concentration 
Given that the A[8] variant showed the greatest increase in KM for CTP binding when the amount of 
tRNAAsp-NC transcript was held constant, we tried the reverse experiment by holding the CTP amount 
constant and altering the tRNAAsp-NC concentration (Table 3-4).  As a result, the A[8] variant showed an 
80-fold increase in KM,Apparent for tRNA
Asp-NC upon fitting to the Michaelis-Menten model when compared 
to the native enzyme (3.01 ± 0.6 µM versus 0.04 ± 0.0 µM).  Interestingly, when the data were analyzed 
based on the Hill model, this difference in KM,Apparent was much less (at approximately 10-fold at 0.47 ± 
0.1 µM), suggesting there may be some cooperativity (Hill coefficient, n = 1.42 ± 0.1) involved in tRNAAsp-
NC binding.  In either case, no major change in kcat was observed (less than three-fold), although less 
product formation was seen in the end point assay (Fig. 3-8).  Based on these data, the specificity 
constants (kcat/KM,Apparent’s) for tRNA
Asp-NC were more than 10-fold lower than that of the native enzyme 
and almost identical within experimental error.  Again, this suggests that overall cooperativity is not an 
issue. 
 
Table 3-4: Kinetic Assay of Native and Variant TRNT1 Enzymes (Varying tRNAAsp-NC and Fixed CTP) 
 
(A) Calculated values. 
(B) Calculated values from (A) normalized to those of native TRNT1.  
All data fitted to Michaelis-Menten model except for a which is fitted to Hill model. 
Note: Green, native values; red, “weaker” than native values. 






3.5 In Silico Folding and Docking of TRNT1 Variants to Bacillus subtilis tRNAAsp-NCCA 
In order to place into context the biophysical and/or biochemical alterations of the TRNT1 enzyme 
variants relative to the native enzyme, in silico folding of these variants was performed using Robetta 
(Kim et al. 2004).  The tertiary structure of the B. subtilis tRNAAsp-NCCA transcript was determined via in 
silico folding of the secondary structure of the transcript by RNAComposer (Popenda et al. 2012), and 
this was followed by in silico docking to the crystal structure of the native enzyme or to the folded 
structure of each variant enzyme using HDOCK (Pearson and Lipman 1988; Remmert et al. 2012; Yan et 
al. 2017). 
 
The models for the R99W variant (discussed further in Section 4.1) suggest a local change in the tertiary 
structure of the protein (Fig. 3-12), display the location of the residue corresponding to R99 relative to 
nearby regions of the native protein (Fig. 3-13), and suggest displacement of one or more disordered 
loop and/or flexible loop residues in the variant protein (Fig. 3-14). 
 
 
Figure 3-12: Local Change in Tertiary Structure of the R99W Variant.  The native TRNT1 enzyme (blue 
ribbon) and R99W variant (red ribbon) are shown superimposed.  The region N-terminal to α-helix 5 (h5) 
for both enzymes is coloured white.  Phenylalanine residues in this region of the proteins (blue and red 
sticks) and the arginine or tryptophan residue at position 99 (light and dark green sticks, respectively) in 






Figure 3-13: Location of the Residue Corresponding to R99, Motifs A and B, the Disordered Loop and 
the Flexible Loop in the Native TRNT1 Enzyme.  (A) The regions to be discussed are shown on the 
primary sequence of TRNT1.  Residue R99 is shown in large font.  The first “DF” residues (red) represent 
the last two amino acids of motif A and the last “DA” residues (orange) represent the first two amino 
acids of motif B.  Based on the crystal structure of Augustin et al. (2003), α-helix 4 (h4) is shown in bold, 
β-strands 2, 3 and 4 (s2, s3 and s4, respectively) are shown in italics and a turn is underlined.  The 
disordered loop (Toh et al. 2009) is displayed in light gray and the flexible loop (Neuenfeldt et al. 2008; 
Hoffmeier et al. 2010) in black.  (B) The native TRNT1 enzyme (blue ribbon) is shown with motif A (red), 
motif B (orange), the disordered loop (light gray) and the flexible loop (black) displayed.  Unresolved 
regions of the crystal structure are indicated as dashed blue lines.  Residue R99 (blue stick) is flanked by 
β-strand 2 (s2) or α-helix 4 (h4) and β-strand 3 (s3).  This structure is visualized by PyMOL (v1.7.4.5) 





Figure 3-14: Displacement of One or More Disordered Loop and/or Flexible Loop Residues by the 
R99W Substitution.  The native TRNT1 enzyme (blue ribbon) and R99W variant (red ribbon) are 
superimposed and their bound tRNAs (light blue and light red lines, respectively) are shown.  Residues 
R99 and W99 are represented by blue and red sticks, respectively.  Oxygen and nitrogen atoms are 
coloured dark red and dark blue, respectively.  (A) In the native enzyme and the R99W variant, the 
disordered loop (white and green, respectively) and the flexible loop (gray and teal, respectively) are 
displayed.  (B, C) In each of these, key residues in the disordered loop and flexible loop are indicated and 
hydrogen bond interactions are represented by dotted lines (displayed lengths in Ångströms).  (D) In the 
native enzyme and the R99W variant, the flexible loop (gray and teal, respectively) and motif D (purple 
and dark blue, respectively) are displayed.  (E, F) In each of these, key residues in the flexible loop and 
motif D are indicated and hydrogen bond interactions are represented by dotted lines (displayed lengths 
in Ångströms).  (In the native enzyme, the lack of a hydrogen bond between R134 and E193 results from 
the absence of R134 in the crystal structure.)  These structures are visualized by PyMOL (v1.7.4.5) 
(Schrödinger 2018) and the native enzyme is a composite of two structures (PDB ID: 4X4W, 1OU5). 
 
The models for the E43Δ variant (discussed further in Section 4.2) suggest an alteration in structure of 
the protein promoted by a loss of a defined α-helix and displacement of an adjacent loop (Fig. 3-15), 
display the location of the residue corresponding to E43 relative to nearby regions of the native protein 
(Fig. 3-16), suggest a shift of the nucleotide binding pocket in the variant protein (Fig. 3-17), 
displacement of one or more disordered loop and/or flexible loop residues (Fig. 3-18), retention of 
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hydrogen bonds between residues R60 and A81 (Fig. 3-19) and displacement of one or more motif C 
residues (Fig. 3-20). 
 
 
Figure 3-15: Loss of Defined Structural Elements of the E43Δ Variant.  (A) The native TRNT1 enzyme 
(blue ribbon) and E43Δ variant (red ribbon) are shown superimposed.  The region between α-helix 1 (h1) 
and α-helix 2 (h2) deviating in space between the structures is coloured white, and residue E43 of the 
native TRNT1 enzyme is coloured green.  (B) In the native TRNT1 enzyme, residue E43 (green stick) at 
the N-terminus of α-helix 2 hydrogen bonds to K46 and S47 (blue sticks) within the helix, where 
hydrogen bonds are represented by dotted lines (displayed lengths in Ångströms).  (C) In the E43Δ 
variant, a lack of stabilizing hydrogen bonds to K46 and S47 might lead to destabilization of α-helix 2 and 
a slight structural change in the loop connecting α-helix 1 to α-helix 2.  In (B) and (C), oxygen and 
nitrogen atoms are coloured dark red and dark blue, respectively.  These structures are visualized by 





Figure 3-16: Location of the Residue Corresponding to E43, Motifs A and C, the Disordered Loop and 
the Flexible Loop in the Native TRNT1 Enzyme.  The native TRNT1 enzyme (blue ribbon) is shown with 
motif A (red), motif C (yellow), the disordered loop (white) and the flexible loop (gray) displayed.  
Unresolved regions of the crystal structure are indicated as dashed blue lines.  Residue E43 (blue stick) is 
situated at the N-terminus of α-helix 2 (h2) and is located C-terminal to α-helix 1 (h1).  This structure is 






Figure 3-17: Shift of the Nucleotide Binding Pocket Relative to the Two-Metal Binding Carboxylates by 
the E43 Deletion.  The native TRNT1 enzyme (blue surface mesh) and E43Δ variant (red surface mesh) 
are superimposed.  (A) In the native enzyme and the E43Δ variant, motif A (pink and light green surface 
mesh, respectively) and motif D (purple and dark blue surface mesh, respectively) are displayed.  (B, C) 
In each of these, the conserved residues in motif A and motif D are indicated.  In the E43Δ variant, the 
nucleotide binding pocket defined by residues E193, D194 and R197 of motif D has an alternative 
structural organization and may pull the bound ATP away from the two-metal binding catalytic 
carboxylates D77 and D79 of motif A.  These structures are visualized by PyMOL (v1.7.4.5) (Schrödinger 





Figure 3-18: Displacement of One or More Disordered Loop and/or Flexible Loop Residues by the E43 
Deletion.  The native TRNT1 enzyme (blue ribbon) and E43Δ variant (red ribbon) are superimposed and 
their bound tRNAs (light blue and light red lines, respectively) are shown.  Residue E43 is represented by 
a blue stick.  Oxygen and nitrogen atoms are coloured dark red and dark blue, respectively.  (A) In the 
native enzyme and the E43Δ variant, the disordered loop (white and green, respectively) and the flexible 
loop (gray and teal, respectively) are displayed.  (B, C) In each of these, key residues in the disordered 
loop and flexible loop are indicated and hydrogen bond interactions are represented by dotted lines 
(displayed lengths in Ångströms).  (D) In the native enzyme and the E43Δ variant, the flexible loop (gray 
and teal, respectively) and motif D (purple and dark blue, respectively) are displayed.  (E, F) In each of 
these, key residues in the flexible loop and motif D are indicated and hydrogen bond interactions are 
represented by dotted lines (displayed lengths in Ångströms).  (In the native enzyme, the lack of a 
hydrogen bond between R134 and E193 results from the absence of R134 in the crystal structure.)  
These structures are visualized by PyMOL (v1.7.4.5) (Schrödinger 2018) and the native enzyme is a 





Figure 3-19: Retention of Hydrogen Bonds between Residues R60 and A81 of the E43Δ Variant.  (A) 
The native TRNT1 enzyme (blue ribbon) and (B) E43Δ variant (red ribbon) are shown.  Motif A (white), 
the flexible loop (green) and motif B (gray) are displayed with residues E43, R60 and A81 represented by 
sticks, where A81 normally makes direct contact with the flexible loop.  The hydrogen bonds between 
the amide and carbonyl groups of the main chains of R60 and A81, which are located on adjacent β-
strands, are retained upon the deletion of E43 and no alteration in the position of the flexible loop is 
apparent.  Hydrogen bonds are represented by dotted lines (displayed lengths in Ångströms), and 
oxygen and nitrogen atoms are coloured dark red and dark blue, respectively.  These structures are 
visualized by PyMOL (v1.7.4.5) (Schrödinger 2018). 
 
 
Figure 3-20: Displacement of One or More Motif C Residues by the E43 Deletion.  The native TRNT1 
enzyme (blue ribbon) and E43Δ variant (red ribbon) are superimposed and their bound tRNAs (light blue 
and light red lines, respectively) are shown.  Residue E43 is represented by a blue stick.  Oxygen and 
nitrogen atoms are coloured dark red and dark blue, respectively.  (A) In the native enzyme and the 
E43Δ variant, motif C (black and deep teal, respectively) is displayed.  (B, C) In each of these, key 
residues in motif C are indicated and hydrogen bond interactions are represented by dotted lines 
(displayed lengths in Ångströms).  These structures are visualized by PyMOL (v1.7.4.5) (Schrödinger 




The models for the A[8] variant (discussed further in Section 4.3) display the location of altered residues 
of the protein from the A[8] frame shift (Fig. 3-21) and reveal newly exposed surfaces of the two C-
terminal α-helices (Fig. 3-22). 
 
 
Figure 3-21: Location of Altered Residues from the A[8] Frame Shift in the TRNT1 Enzyme.  The native 
TRNT1 enzyme (blue ribbon) and A[8] variant (red ribbon) are superimposed and their bound tRNAs 
(light blue and light red lines, respectively) are shown.  In the tail domain, the 17 C-terminal residues 
(white) of the native enzyme and the eight C-terminal residues (gray) of the A[8] variant are displayed.  
(A) The bound tRNAs of the native enzyme and the A[8] variant reveal a large difference in rotational 
position.  (B) In the A[8] variant, the C-terminal α-helix is replaced by a small disordered region.  These 
views of the native enzyme and the A[8] variant are shown separately in (C) and (D), respectively.  In (B-
D), the molecular complex is rotated 180° relative to (A) with respect to the vertical.  These structures 





Figure 3-22: Newly Exposed Surfaces of the Two C-Terminal α-Helices of the A[8] Variant.  (A, C) In (A), 
the three C-terminal α-helices (h20, h21 and h22 as cyan ribbons) of the tail domain in the native TRNT1 
enzyme and bound tRNA (light blue lines) are shown.  In (C), residues of h20 and h21 which interact with 
h22 are represented by sticks.  (B, D) In (B), the two C-terminal α-helices (h20 and h21 as cyan ribbons) 
of the tail domain in the A[8] variant and bound tRNA (light red lines) are shown.  In (D), the same 
residues of the α-helices from (C), with the exception of residue K418 resulting from the A[8] frame 
shift, are surface-exposed and are represented by sticks.  Carbon, α-carbon, oxygen and nitrogen atoms 
are coloured purple, cyan, dark red and dark blue, respectively.  These structures are visualized by 











In eukaryotes, the role of tRNA nucleotidyltransferase (tRNA-NT) is paramount in the fundamental 
functioning of the cell as tRNAs must undergo an essential maturation step in which a cytidine-cytidine-
adenosine (CCA) trinucleotide sequence is attached to the 3’-end of each tRNA.  This specific series of 
nucleotide additions is accomplished by tRNA-NT without the need for a nucleic-acid template 
(Deutscher 1983).  Partial loss-of-function (LOF) mutations in TRNT1, encoding human tRNA-NT, have 
been demonstrated to cause a wide spectrum of human diseases, as evidenced by the rapidly growing 
body of medical literature in the past five years (Aksentijevich et al. 2014; Chakraborty et al. 2014; 
Sasarman et al. 2015; DeLuca et al. 2016; Hull et al. 2016; Wedatilake et al. 2016; Frans et al. 2017; 
Lougaris et al. 2018; Giannelou et al. 2018; Bader-Meunier et al. 2018; Gorodetsky et al. 2018; Kumaki et 
al. 2019; Abdulhadi et al. 2019). 
 
SIFD, the most severe of these disease phenotypes, has been recently linked to reduced thermal 
stabilities and catalytic activities of TRNT1 enzyme variants (Leibovitch et al. 2018, 2019) that arise from 
six single amino acid substitutions (T154I, M158V, L166S, R190I, I223T and I326T) first identified by 
Chakraborty et al. (2014).  Of these substitutions, the first five map within or close to the active site in 
the head and neck domains of the protein, while the last (I326T) maps further from the active site in the 
body domain.  Despite their different locations in the protein, all of these substitutions lead to decreases 
in thermal stability and/or catalytic activity. 
 
In light of these observations, this work explores three additional TRNT1 mutations yielding the E43Δ 
(DeLuca et al. 2016), R99W (Aksentijevich et al. 2014; Hull et al. 2016; Frans et al. 2017; Kumaki et al. 
2019) and A[8] (Chakraborty et al. 2014; DeLuca et al. 2016; Giannelou et al. 2018) variants.  These 
amino acid changes map near the amino-terminus (E43Δ), between conserved motifs A and B in the 
head domain but far from the previously characterized mutations (R99W), and to the tail domain far 
from the active site of the protein (A[8]).  Moreover, these changes result from a three-nucleotide 
deletion (E43Δ), a missense mutation (a single cytosine-to-thymine transition generating R99W) and a 
frame shift resulting from a single nucleotide insertion (A[8], eight adenosines instead of seven).  By 
exploring these three variants resulting from different types of mutations found near the amino-
terminus (N-terminus), the active site or the carboxy-terminus (C-terminus) of the resulting protein, we 
hoped to see effects on enzyme structure and/or function to determine potential contributions to 
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TRNT1-linked pathogenesis and to see if there are unifying features linked to pathogenesis, regardless of 
the type or location of mutation introduced. 
 
4.1 R99W Variant 
The R99W variant will be discussed first as it is found near the active site as are the T154I, M158V, 
L166S, R190I and I223T variants which have been characterized previously (Leibovitch et al. 2018).  The 
R99W variant results from a transition at nucleotide position 295 in the TRNT1 open reading frame 
where a cytosine is converted to a thymine changing a CGG codon to UGG (Aksentijevich et al. 2014; 
Hull et al. 2016; Frans et al. 2017; Kumaki et al. 2019).  Located between conserved motifs A and B (Figs. 
1-3, 3-13A), R99 is situated in an unstructured region between strands 2 and 3 of the single antiparallel 
β-sheet of the enzyme and based on the available crystal structures of TRNT1 (Augustin et al. 2003; 
Kuhn et al. 2015) is found on the surface of the protein (Fig. 3-13B).  Substitution of this hydrophilic 
amino acid in the primary-sequence context of alanine-glycine-isoleucine-arginine-methionine-
isoleucine (Figs. 1-3, 3-13A) with the more hydrophobic tryptophan residue (Engelman et al. 1986) may 
be expected to lead to a reorganization of this region of the protein and the movement of these amino 
acids into a more hydrophobic environment.  This reorganization may be expected to alter nucleoside 
triphosphate (NTP) binding or discrimination as motif A contains the two-metal binding catalytic 
carboxylates (DxD) that interact with the triphosphate moiety of CTP or ATP (Steitz et al. 1994; Yue et al. 
1996; Steitz 1998), while motif B contains the residues required to ensure that deoxyribonucleoside 
triphosphates (dNTPs) do not bind (Li et al. 2002; Cho et al. 2007).  Moreover, it has been proposed that 
this region of the protein contains a flexible loop that acts to ensure complete CCA addition by changing 
conformation during CMP and AMP incorporation (McGann and Deutscher 1980; Zhu et al. 1986; Li et al. 
2002; Augustin et al. 2003; Tomita et al. 2004; Neuenfeldt et al. 2008; Just et al. 2008; Toh et al. 2009; 
Hoffmeier et al. 2010). 
 
4.1.1 Local Change in Tertiary Structure 
Rearrangement of this region of the protein may have changed the environments of other aromatic 
amino acids in the vicinity of position 99 (e.g., F93, or F80 and F120 in the single β-sheet) such that their 
fluorescence spectra were altered, changing the fluorescence intensity or the wavelength of the 
maximum fluorescence signal.  Also, given that in this study we used the mature TRNT1 enzyme (lacking 
its mitochondrial targeting signal (MTS)) such that it contains only four tryptophan residues (W144 in 
motif B, W239 in motif E, and W381 and W415 in the C-terminal tail domain), the addition of a fifth 
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tryptophan may have been expected to change the fluorescence signal more dramatically after 
excitation at 295 nm, since at this wavelength tryptophan fluorescence dominates over that of 
phenylalanine or tyrosine.  Surprisingly, when assayed for excitation at 295 nm, the fluorescence 
maximum for tryptophan, there was no real red-shift of the fluorescence signal (~1.5 nm), suggesting no 
major change in overall higher order structure and surprisingly no effect of adding an additional 
tryptophan residue to the protein.  More interestingly, a larger change in wavelength of fluorescence 
maximum of approximately 3 nm (Fig. 3-6, with or without RNase) was seen after excitation at 280 nm 
(which should excite phenylalanine, tryptophan and tyrosine).  Given that there was no major change in 
fluorescence seen with the excitation at 295 nm which suggested no dramatic alteration of the overall 
structure of the protein, the change in fluorescence maximum after excitation at 280 nm may be linked 
to a more localized rearrangement of tyrosine and phenylalanine residues.  If one concentrates on the 
region near R99 and N-terminal to α-helix 5 (helix numbering according to Augustin et al. (2003)), one 
notes that this region contains seven phenylalanine residues (accounting for one third of all 
phenylalanines in TRNT1), one tryptophan and no tyrosines.  Importantly, this region of the protein 
includes the disordered region containing R99 and most of the single β-sheet found in TRNT1 (Fig. 3-12).  
The red-shift in wavelength of the emission maximum indicates that some aromatic residues have been 
moved into a more hydrophilic environment perhaps resulting in a reorganization of this important 
region. 
 
4.1.2 Dimerization as a Probe for Determining Biophysical Properties 
Recently, Leibovitch et al. (2019) showed that even a small change in tertiary structure could manifest 
itself in the inability of TRNT1 to form a covalent dimer in vitro, so we checked for dimerization of the 
R99W variant.  Similar to the native protein, the R99W variant was capable of forming a covalent dimer 
under non-reducing conditions (Fig. 3-2), and native PAGE suggests no apparent change in size or 
conformation of the R99W monomer or dimer as compared to those of the native enzyme (Fig. 3-3).  
This is not surprising as substitutions of other amino acids (T154I, M158V, L166S, R190I and I223T) 
clustering near the active site also did not inhibit covalent dimer formation (Leibovitch et al. 2019).  
Given that dimerization requires the presence of residue C373 found at the C-terminal end of the body 
domain far from R99, this again supports the idea that the change of R99 to tryptophan does not result 
in major structural changes in the protein, again suggesting that a local change in structure (Fig. 3-12) is 




The loss of covalent dimerization in vitro was also linked to a decrease in tRNA binding in the I326T 
variant (Leibovitch et al. 2019), however, as the R99W variant and the native enzyme show similar 
A280:A260 ratios before or after RNase treatment (Fig. 3-4), this suggests a similar level of binding of the 
tRNA substrate to the enzyme during purification and supports the hypothesis that the change in the 
enzyme is confined to the N-terminal region of the head domain far from where tRNA binds. 
 
4.1.3 No Change in Secondary Structure but Minor Decrease in Stability 
The data to this point support a change in higher order structure confined to a small region of the 
protein rather than reflecting a major change in higher order structure.  To see if this change is revealed 
in a loss or gain of specific secondary structures, we used circular dichroism (CD) spectroscopy.  Based 
on a comparison of the CD spectra of the native and variant enzyme, no change in the secondary 
structure of the R99W variant was detected (Fig. S3 A-C).  In addition, we used CD spectra to determine 
the thermal stability of the native and variant enzymes.  We noted that there was a greater difference in 
melting temperature within the native enzyme with or without RNA (~2.5°C) than there was between 
the R99W variant and the native enzyme (<1°C) under either of these conditions (Fig. 3-5).  This is a 
novel observation with respect to amino acid substitutions near the active site, as the other 
characterized variants all showed a drop of 5-7°C in melting temperature as compared to the native 
enzyme (Leibovitch et al. 2018).  However, this observation fits well with the finding that production of 
the R99W variant protein is normal in skin-derived fibroblasts in one male patient with progressive B-cell 
immunodeficiency, who is homozygous for R99W (Table 1-1), suggesting that thermal instability does 
not lead to pathogenesis in this case (Frans et al. 2017).  The increase in Tm seen when either sample 
was compared to its non-RNase treated counterpart (Fig. 3-5) likely reflects a contribution from bound 
tRNA in thermal denaturation as more energy is needed in the presence of tRNA to denature both the 
tRNA and the protein. 
 
As no dramatic alteration was observed in any of the biophysical parameters we tested (secondary, 
tertiary or quaternary structure, thermal stability, or the amount of tRNA associated with the R99W 
variant as compared to the native TRNT1 enzyme), this suggested that neither a major loss of structure 
nor stability was responsible for the phenotype observed.  Therefore, we proceeded to gauge the level 





4.1.4 Altered CMP and AMP Incorporation 
Previous in vitro characterizations of the T154I, M158V, L166S, R190I, I223T and I326T variants have all 
revealed, to various degrees, decreased AMP incorporation onto the B. subtilis tRNAAsp-NCC and -NC 
transcripts (Leibovitch et al. 2018, 2019).  Based on the location of the R99 residue between conserved 
motifs A and B in the catalytic core of the enzyme (Fig. 3-13), the R99W substitution may also affect 
enzyme activity. 
 
Indeed, reduced A-addition onto the tRNAAsp-NCC was seen with the R99W variant as compared to the 
native enzyme in end point assays (Fig. 3-7).  At the highest enzyme amount tested (~10 ng), the R99 
variant showed three-fold less product formation as compared to the native enzyme.  This suggests that 
the ability to either bind or incorporate AMP is affected.  Given the role of motif A in binding the 
triphosphate portion of NTPs, and the role of the region between motifs A and B in allowing the switch 
from C-addition to A-addition (Toh et al. 2009; Hoffmeier et al. 2010), these observations were not 
surprising.  We wished to know if the reduced ability to incorporate AMP also was seen with CMP 
incorporation and so assayed for C-addition to the tRNAAsp-NC (Fig. 3-8) and tRNAAsp-N transcripts (Fig. 3-
9).  When looking at the addition of two C residues, at any enzyme amount tested, CMP incorporation 
was comparable between the native enzyme and the R99W variant (Fig. 3-9).  Moreover, when we used 
the tRNAAsp-NC transcript and added a single C residue, we saw perhaps even more efficient 
incorporation of the second C by the R99W variant than by the native enzyme (Fig. 3-8).  This suggests 
that the defect in this enzyme is reflected in AMP incorporation and not in CMP incorporation.  This is 
supported when both ATP and CTP are incubated with the tRNAAsp-N transcript, as similar levels of CMP 
seem to be incorporated while almost no AMP is incorporated by the R99W variant (Fig. 3-10).  In order 
to characterize this decrease in A-adding activity, kinetic assays were performed. 
 
4.1.5 Kinetic Analysis and Possible Mechanisms of TRNT1 Alteration 
As the end point assays suggested that A-addition was the limiting factor, we first characterized AMP 
incorporation onto the tRNAAsp-NCC transcript.  The kcat that we calculated for AMP incorporation by the 
R99W variant suggested that less efficient chemistry of the reaction may play some role in generating 
the phenotype observed, as the R99W variant showed a turnover number (kcat) that was approximately 
20% that of the native enzyme (Table 3-1).  A five-fold reduction in turnover number correlates well with 
the reduced AMP incorporation that we saw in the end point assays (Fig. 3-7).  Previously, an E. coli 
tRNA-NT variant has been identified which showed an approximately five-fold decrease in the ability to 
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incorporate AMP but not CMP (McGann and Deutscher 1980), and the amino acid alteration was 
determined to be a glycine-to-aspartic acid substitution in the GxGxxG nucleotide-binding domain of the 
E. coli tRNA-NT which also is in the region between motifs A and B (Zhu et al. 1986).  Also, with the E. 
coli enzyme, Kim et al. (2009) have carried out single turnover kinetics and have shown that the kinetics 
of AMP incorporation depends on pre-chemistry conformational changes of the active site.  By carrying 
out the experiment in increasing glycerol concentrations, they showed that they could decrease the 
incorporation of AMP by approximately five-fold, similar to what we saw here with the R99W variant.  
Moreover, under the same experimental conditions they have seen no effect on CMP incorporation.  
When this same region of the E. coli tRNA-NT was replaced with the corresponding region of the E. coli 
poly(A) polymerase, AMP incorporation but not CMP incorporation was lost (Just et al. 2008).  
Neuenfeldt et al. (2008) further have shown that a small deletion in this region of the E. coli enzyme 
near what would be R99 in the human enzyme between motifs A and B resulted in the loss of the ability 
to incorporate AMP but not CMP, again suggesting the loss of an ability to alter the conformation of this 
region of the protein to switch from CMP to AMP incorporation during the course of the reaction.  
Furthermore, they also have indicated (data not shown, Neuenfeldt et al. (2008)) that additional 
mutations in the corresponding region of the human enzyme also interfere dramatically with A-addition.  
Taken together, all of these observations suggest that the ability to alter the conformation of the 
enzyme to incorporate AMP but not CMP is impaired in the R99W variant. 
 
Interestingly, while the turnover number for AMP incorporation was reduced approximately five-fold in 
the R99W variant as compared to the native enzyme, an even more dramatic change (approximately 
100-fold smaller) in the apparent Michaelis constant (KM,Apparent) for ATP binding was observed in the 
R99W variant as compared to the native enzyme (Table 3-1).  This much smaller KM,Apparent for the variant 
as compared to the native enzyme suggests that ATP binds more tightly to the R99W variant than it does 
to the native enzyme.  It is difficult to reconcile this increase in ATP binding with the decrease in specific 
activity that we observed, but it may reflect the decreased ability of the variant enzyme to perform the 
conformational changes required during the course of the reaction.  If we consider that under the 
conditions for this reaction (Eq. 1), k2 is not rate-limiting, then KM,Apparent is defined by Eq. 2, 
 
           Eq. 1 
 
           Eq. 2 
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where E, S, ES and P represent enzyme, substrate, enzyme-substrate complex and product, respectively.  
Thus, KM,Apparent ≈ k-1/k1 and the ~100-fold decrease in KM,Apparent for the variant as compared to the native 
enzyme may reflect either a much smaller rate of substrate release or a much greater rate of substrate 
binding.   The significance of this decrease in KM,Apparent and how the R99W substitution leads to it 
remains unclear, but perhaps the conformational change that reduces the turnover number does so by 
more tightly binding the ATP substrate. 
 
As the experiments described above all suggest that amino acid substitutions in this region of the 
protein reduce activity with respect to AMP incorporation but not CMP incorporation, we also wanted 
to test for changes in any kinetic parameters associated with CMP incorporation.  As we previously saw 
an apparent increase in catalytic activity for CMP incorporation in our end point assay (Fig. 3-8), we 
were not surprised to see a nine-fold increase in the specificity constant (kcat/KM,Apparent) for CMP 
incorporation onto the tRNAAsp-NC transcript owing largely to a 20-fold increase in affinity (e.g., 20-fold 
decrease in KM,Apparent) for CTP (Table 3-2).  These parameters for CMP incorporation, when taken with 
those for AMP incorporation (Table 3-1), suggest that while there is a small decrease in kcat in either 
case, there is a much more important change in KM,Apparent especially for AMP incorporation.  As 
discussed, this change in KM,Apparent reflects either a much greater recognition and binding of substrate or 
a much reduced rate of substrate release.  The fact that both ATP and CTP binding seem to be increased 
in the R99W variant suggests that this amino acid substitution in part alters the organization around the 
NTP-binding DxD sequence in motif A (Li et al. 2002).  In fact, our data suggest that these decreases in 
KM,Apparent (e.g., increases in affinity) are limited to NTPs, as when KM,Apparent was calculated for tRNA
Asp-
NCC binding, an 11- or 2-fold increase in KM,Apparent (e.g., decrease in affinity) was instead observed in 
comparison to the native enzyme (Table 3-3).  The differences in the binding of ATP and CTP may reflect 
changes in motif D which is responsible for distinguishing between these two bases (Li et al. 2002), but 
as described above, changes in conformation during the course of the reaction also may be involved. 
 
An intriguing possibility may involve the role of a disordered region in the structure between motifs A 
and B (Fig. 3-13) in contributing to the bias toward CMP incorporation.  In the T. maritima tRNA-NT, a β-
turn links strands 4 and 5 in the single β-sheet in this protein, and residues within this β-turn have been 
proposed to play a role in the recognition of the phosphate backbone of the 3’-end of the bound tRNA 
during CMP incorporation and the subsequent positioning of the tRNA 3’-end for AMP incorporation 
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(Toh et al. 2009).  When this region of the T. maritima protein is compared to that of the human enzyme 
(Fig. 4-1), we see that this β-turn aligns well with the disordered region in the human enzyme. 
 
 
Figure 4-1: Sequence Alignment of a Region of the Human and Thermotoga maritima tRNA-NTs.  
Residue R99 in the human enzyme is shown in bold.  The disordered region in the human enzyme is 
underlined once and the β-turn in the T. maritima enzyme is underlined twice.  Residue T87 in the β-
turn is displayed in bold and green. 
 
Upon substitution of a threonine residue at position 87 within this β-turn (Fig. 4-1) by alanine, Toh et al. 
(2009) demonstrated slightly augmented C-addition and reduced A-addition into T. maritima tRNAPhe-
derived mini-helices initially ending with -N or -NC and -NCC, respectively.  As this threonine residue has 
been shown to form a hydrogen bond with R104 of the flexible loop, which in turn rearranges the 
nucleotide binding pocket formed by motif D to facilitate ATP binding and fixes the tRNA 3’-end during 
AMP incorporation, the replacement of the threonine in this loop might have abolished this hydrogen 
bond and weakened incorporation of AMP in the T. maritima tRNA-NT (Toh et al. 2009).  Given the 
alignment of this β-turn with the disordered region of TRNT1 (Fig. 4-1), a similar scenario may occur with 
TRNT1.  The R99W substitution in TRNT1 might lead to a rearrangement of the disordered loop that 
leads to displacement of one or more functionally critical residues (Fig. 3-14 A-C) such that the 
disordered loop can no longer reposition the 3’-end of the tRNA for AMP incorporation, resulting in 
augmented CMP incorporation and reduced AMP incorporation.  This suggests that the important 
change seen in the R99W variant is in the arrangement of the amino acids required to align the 
substrates appropriately for catalysis rather than simply in the binding of the substrates. 
 
The altered incorporation of CMP and AMP, respectively, may also reflect changes in the flexible loop of 
TRNT1 that result when R99 is changed to tryptophan.  Given the position of the R99 residue and the 
flexible loop between motifs A and B (Fig. 3-13), it is conceivable that the R99W substitution might also 
disrupt the function of the flexible loop.  The flexible loop, located near the β-sheet, is highly disordered 
and non-resolved in most crystal structures of Class II tRNA-NTs (Fig. 3-13).  It consists of 10 to 20 amino 
acids and lacks sequence conservation (Li et al. 2002; Augustin et al. 2003; Tomita et al. 2004; 
Neuenfeldt et al. 2008; Toh et al. 2009), but is demonstrated to directly interact with conserved residues 
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of motif D.  It is known to effectuate a lever-like motion that triggers movement of these conserved 
residues, thus rearranging the nucleotide binding pocket of motif D for a CTP-to-ATP specificity switch. 
The flexible loop initially detects and fixes the tRNA 3’-end after two rounds of C-addition, and 
subsequently promotes terminal A-addition by mediating the movement of adjacent domains of the 
enzyme (Neuenfeldt et al. 2008; Toh et al. 2009; Hoffmeier et al. 2010) (Fig. 1-4).  Supporting what has 
been described above for the importance of hydrogen bonding between T87 and R104 in the T. 
maritima tRNA-NT, conversion of R104 of the flexible loop to alanine also showed reduced AMP 
incorporation at the 3’ terminal position of a T. maritima tRNAPhe-derived mini-helix although the rate of 
CMP incorporation was unchanged at the penultimate position (Toh et al. 2009).  In addition, these 
authors have shown that upon replacing Y108 of the flexible loop with alanine, AMP incorporation was 
reduced to below 30% of that of the native T. maritima tRNA-NT.  Both of these scenarios demonstrate 
that single amino acid substitution can lead to the loss of the ability of the flexible loop to direct the 
nucleotide binding pocket of motif D to switch from CTP to ATP specificity.  Since R104 of the T. 
maritima tRNA-NT is also part of the highly conserved B/A motif of CCA-adding enzymes (Neuenfeldt et 
al. 2008) and Y108 is mildly conserved among these (Hoffmeier et al. 2010), a similar scenario might 
occur with TRNT1.  With respect to the flexible loop in the human enzyme, Hoffmeier et al. (2010) have 
shown that alanine substitutions at D132, G133 or R134 (numbering as in Augustin et al. (2003)) in this 
region of the human enzyme almost completely abolish AMP incorporation at the 3’ terminal position, 
while CMP incorporation at the two preceding positions remains intact.  All of these results agree well 
with what we observed for the R99W variant in end point assays where AMP incorporation was reduced 
while CMP incorporation was not (Figs. 3-7 to 3-9).  Taken together, these data suggest that the R99W 
substitution in TRNT1 might propagate a conformational change via tertiary structural alterations that 
displaces residues R126 and/or T131 (homologues of R104 and Y108 in the T. maritima tRNA-NT, 
respectively) in the flexible loop (Fig. 3-14 D-F), such that the flexible loop becomes unable to induce the 
switch of the nucleotide binding pocket to ATP specificity.  Mechanistically, R134 in the human enzyme 
is responsible for inducing the nucleotide specificity switch of motif D by forming a salt bridge to the 
conserved E193 residue in the nucleotide binding pocket to bring the head and neck domains together 
(Hoffmeier et al. 2010).  Considering what we have seen for C- and A-addition by the R99W variant in 
our end point assays, it is plausible that the R99W substitution might effect a conformation change that 
displaces D132, G133 and/or R134 (Fig. 3-14 D-F) with the end result being the inability of the flexible 




However, the problem with this interpretation is that we see an approximately 100-fold decrease in 
KM,Apparent for ATP in the R99W variant as compared to the native enzyme.  This suggests that reduced 
ATP binding is not the issue, but rather catalysis (an approximately five-fold decrease in kcat for AMP 
incorporation was observed in the R99W variant).  In the experiments of Hoffmeier et al. (2010) with the 
human enzyme, they also showed a decrease in KM for ATP binding (albeit much smaller at 30-60% for 
the T130A and R134A variants, respectively) with a much more dramatic decrease in kcat (by 77-fold) for 
the R134A variant.  Based on their observations, Hoffmeier et al. (2010) proposed that in addition to 
being involved in the switch from CTP binding to ATP binding, the loop element also contributed to the 
catalysis of A-addition.  This is supported by our observation of an approximately five-fold reduction in 
kcat and crystallographic studies with bound substrates (Toh et al. 2009) indicating that in the T. 
maritima enzyme the loop was involved in positioning the 3′-OH group of the final cytidine residue (C75) 
of the tRNA for nucleophilic attack on the triphosphate moiety of the ATP that also is bound to the 
enzyme. 
 
In summary, it appears that the R99W variant can still bind ATP and CTP efficiently, however, the 
mechanism that prevents efficient incorporation of AMP likely involves the lack of correct local 
conformational changes allowing the nucleotide specificity switch from CTP to ATP, as well as a lack of 
correct local structural changes that direct its catalysis.  Both of these instances suggest that multiple 
structural elements or motifs, in the N-terminal region of TRNT1, are implicated in the impairment of 
AMP incorporation. 
 
4.1.6 The R99W Variant Is Associated With Mild Phenotypes 
Taking into account the small biophysical and biochemical changes in the R99W variant that we report 
here, it is not surprising that the resultant phenotypes linked to this substitution are mild compared to 
those linked to other reported mutations (Table 1-1) (Chakraborty et al. 2014).  Indeed, Leibovitch et al. 
(2018) have shown reduced thermal stability for the T154I variant which is likely to account for its 
significantly reduced level in cultured patient fibroblasts as reported by Chakraborty et al. (2014).  
Meanwhile, the more severe I223T variant exhibited a 20-fold decrease in affinity for CTP binding and 
has been suggested to be detrimental in blood cells where CTP concentrations are relatively low 
(Leibovitch et al. 2018).  That no aberration in thermal stability or dramatic decrease in affinity for CTP 
or ATP was observed for the R99W variant is likely indicative of the mild clinical manifestations (and lack 
of fatalities) associated with this variant.  Upon identifying a male patient homozygous for R99W who 
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was diagnosed at 23 years of age, Frans et al. (2017) suggested that the mild phenotype was linked to a 
lack of conservation of this residue and its surrounding primary sequence (Fig. 1-3).  Three young 
siblings homozygous for R99W also show a mild systemic phenotype (Table 1-1) (Hull et al. 2016).  The 
remaining patients, though, display a different set of symptoms including more systemic pathologies 
such as anemia (Aksentijevich et al. 2014) and autoinflammation (Kumaki et al. 2019) (Table 1-1).  In the 
latter cases, however, R99W is compound heterozygous with another allele and so it is likely that the 
partial LOF of the other mutation also contributes to these phenotypes.  Nonetheless, all patients exhibit 
a form of immunodeficiency (Table 1-1) and thus it is conceivable that, although not lethal, phenotypes 
arising from an R99W substitution may appear in B- and/or T-cells in which high levels of protein 
synthesis continually occur (Kumaki et al. 2019) and therefore are particularly sensitive to perturbations 
in the amount of functional enzyme. 
 
Hence, it is likely that the patients harboring the allele for the R99W substitution are sick due to 
inefficient AMP incorporation by the variant enzyme, as demonstrated by the five-fold decrease in 
turnover number with ATP as a substrate relative to that of the native enzyme (Table 3-1).  That this 
particular facet of the enzyme is only mildly compromised may therefore explain why disease 
manifestations are non-life threatening in patients and are limited in scope and severity. 
 
4.2 E43Δ Variant 
The E43Δ variant results from the deletion of nucleotides 126 to 128 (AGA) in the TRNT1 open reading 
frame such that a single glutamate residue is lost (DeLuca et al. 2016).  This is the most N-terminal 
mutation discovered to date as the original glutamate represents the 14th residue of the probable 
cytosolic form of the protein synthesized from its second N-terminal in-frame start codon.  (The variant 
proteins used in these experiments also are synthesized from this start codon).  In vivo, it is possible that 
the glutamate is even more N-terminal, depending on how many amino acids are removed by the 
mitochondrial processing protease upon import of this protein into mitochondria.  E43 is situated at the 
N-terminus of α-helix 2 of the enzyme and is located N-terminal to conserved motif A (Fig. 1-3).  Based 
on the crystal structures of TRNT1 (Augustin et al. 2003; Kuhn et al. 2015), E43 is surface-exposed (Fig. 
1-6).  Deletion of this negatively charged amino acid from the vicinity of the N-terminus of α-helix 2 may 
lead to destabilization of this helix or may alter the organization of α-helices 1 and 2 with respect to one 
another.  In either event, this change may alter some of the conformational character of this region of 
the protein.  Given that the C-terminus of α-helix 2 is separated by only three amino acids from the N-
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terminus of β-strand 1 that begins at motif A, perhaps changes in the stability or arrangement in space 
of α-helix 2 are propagated through the protein to alter this β-sheet or more specifically motif A. 
 
We previously have shown that in yeast tRNA-NT, an arginine-to-tryptophan substitution at the 
beginning of motif A and in the first β-strand (corresponding to a substitution only 17 amino acids from 
E43 in TRNT1) can suppress a temperature-sensitive (ts) mutation in motif C (Goring et al. 2013).  This 
suppression is linked to an increase in enzyme activity and not to an increase in the thermal stability of 
yeast tRNA-NT.  More precisely, this yeast R64WE189F double variant showed on the order of a 6- to 10-
fold increase in the turnover number (depending on the substrate tested) as compared to the E189F ts 
variant (Rahman 2017).  Furthermore, we have shown that the R64W variant increased 
misincorporation of AMP onto a growing 3’ CCA-end (Rahman 2017).  We wondered if the removal of 
the glutamate from a similar position in TRNT1 (close to the β-sheet and motif A) would show a similar 
effect. 
 
Given the importance of the two-metal binding catalytic carboxylates (DxD) in motif A (Steitz et al. 1994; 
Yue et al. 1996; Steitz 1998), altering the structure of this region of the protein may result in altered NTP 
binding or discrimination.  If this change in structure is not confined to this region of the protein, we 
may also see effects on tRNA binding and catalysis as other important motifs are reoriented in space.  To 
address these possibilities, we first looked at the stability and higher order structure of the E43Δ variant 
as compared to the native enzyme. 
 
4.2.1 Minor Decrease in Structural Stability 
Although we previously have shown that converting R64 to W64 in the yeast enzyme did not alter the 
protein structure or stability (Goring et al. 2013), we wished to confirm that this also was the case in the 
human E43Δ variant and so we proceeded to assess these characteristics using CD spectroscopy and 
thermal denaturation, respectively.  No change in secondary structure of the E43Δ variant was seen (Fig. 
S3 A-C) though a minor drop in melting temperature (~2°C) from that of the native enzyme was 
observed (Fig. 3-5).  Although this change in Tm is considerably less than the 5-7°C drop seen in other 
characterized human variants (Leibovitch et al. 2018, 2019), it is more pronounced than that of the 
R99W variant described above (Fig. 3-5).  If the reduced negative charge resulting from the removal of 
E43 at the N-terminus of α-helix 2 (Fig. 3-15A) destabilizes this helix, it also may eliminate the potential 
for hydrogen bonding between E43 and K46 (via the side chains) and S47 (via the main chain of E43) in 
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α-helix 2 (Fig. 3-15B) to further destabilize the structure of α-helix 2, and also alter the arrangement of 
the connecting turn between α-helices 1 and 2 (Fig. 3-15 A, C).  This modeling agrees well with the 
structural model generated by DeLuca et al. (2016) (who have used an alternative modeling software). 
 
A subsequent propagation of these conformational changes within the protein might thus account for 
the minor decrease in stability, though it remains unclear whether this effect could be global or simply 
confined to one or more regions, as thermal stability was determined based on the change in signal 
intensity at 222 nm reflecting the loss of α-helical character.  This minor decrease in thermal stability is 
consistent with the finding that E43Δ variant protein levels were reduced by over two-fold, as compared 
to native protein levels in fibroblasts in a healthy control, in dermal fibroblasts in one male patient with 
retinitis pigmentosa who exhibited a compound heterozygous E43Δ/c.1246A[6] genotype (Table 1-1) 
(DeLuca et al. 2016).  However, E43Δ variant protein levels are significantly reduced in induced 
pluripotent stem cell (iPSC)-derived retinal organoids specific for this patient, as compared to native 
protein levels in control retinal organoids from an age-matched individual (Sharma et al. 2017), 
suggesting that the stability of the protein in general may be reduced.  These reports suggest that the 
overall reduced stability of the E43Δ variant contributes to pathogenesis involving retinitis pigmentosa.  
In fact, DeLuca et al. (2016) have shown that knockdown of the tRNA-NT gene in zebrafish leads to more 
pronounced defects in the visual response than in other affected cells or tissues, similar to the effect of 
reduced E43Δ variant protein levels in the human patient.  Moreover, DeLuca et al. (2016) have 
demonstrated that while a relatively mild knockdown of the tRNA-NT gene restricts phenotypes to the 
visual system in zebrafish, a more complete knockdown encompasses multiple systems and processes 
including eye development, heart development and red blood cell maturation suggesting therefore a 
dependence of phenotypes on TRNT1 protein levels in humans, or in this specific case, stability of the 
E43Δ variant. 
 
4.2.2 No Change in Tertiary Structure 
To see if the reduced stability of the protein resulted from altered tertiary structure, fluorescence 
spectroscopy was used.  As E43 is found near the N-terminus of the protein, it seemed unlikely that the 
loss of this amino acid would have an effect on the overall tertiary structure of the protein, but a 
rearrangement of this region may have affected the environments of nearby aromatic amino acids (e.g., 
F37, F41, F52 and F93, or F80 in the single β-sheet) such that their fluorescence spectra at 295 nm were 
shifted.  The wavelength of maximum fluorescence of the E43Δ variant upon excitation at either 280 or 
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295 nm revealed no substantial change (~1 nm or less) compared to that of the native enzyme (Fig. 3-6), 
suggesting no major change in overall higher order structure.  These findings suggest limited effects on 
the tertiary structure of the protein either resulting from any destabilization of α-helix 2 or 
rearrangement of the region connecting α-helices 1 and 2 due to the deletion of E43. 
 
4.2.3 No Change in Dimerization or tRNA Binding 
Given that there were no apparent changes in secondary or tertiary structure and that the ability to 
form a covalent dimer in vitro depends on interactions in the C-terminal portion of the enzyme far from 
E43, we did not expect to see any effect on dimerization in the E43Δ variant and this was the case (Fig. 
3-2).  In addition, no apparent change in the size or conformation of the E43Δ monomer or dimer was 
seen as compared to those of the native enzyme (Fig. 3-3).  Based on these data it appears that, as with 
the R99W variant, the E43Δ variant shows no major structural changes. 
 
Similarly, as the loss of in vitro dimerization for the I326T variant reflected a decrease in tRNA binding 
(Leibovitch et al. 2019), like the R99W variant, the E43Δ variant instead shows A280:A260 ratios similar to 
those of the native enzyme before or after RNase treatment (Fig. 3-4).  This suggests a similar level of 
binding of the tRNA substrate to the E43Δ variant during purification and also supports the notion that 
overall structural changes in the protein are minimal. 
 
4.2.4 Altered CMP and AMP Incorporation 
As described previously, we have already characterized the differences in enzyme activity in a yeast 
enzyme with amino acid substitutions in this region of the protein.  More specifically, in the yeast R64W 
variant we have seen no change in turnover number, tRNA or ATP binding, but an approximately three-
fold increase in KM,Apparent for CTP binding (Rahman 2017).  While R64 is predicted to lie within motif A 
and the first β-strand of the β-sheet, E43 in the human enzyme is N-terminal to and separated from 
motif A by α-helix 2 and a short connecting segment (Fig. 3-16).  Hence, it is possible that the deletion of 
E43 in TRNT1 may affect enzyme activity via a structural perturbation of motif A by weakening the 
normal functions of motif A in NTP binding and/or polymerization.  In addition, since in the higher order 
structure of the protein, E43 is not far from the region connecting motifs A and B, or motif C (Fig. 3-16), 
it is possible that these structures may be functionally affected as well.  As described in Section 4.1, the 
region between motifs A and B may be involved in the recognition of the tRNA 3’-end for AMP 
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incorporation at its terminal position.  In addition, motif C is known to mediate this process by bringing 
the head and neck domains of the enzyme together (Ernst et al. 2015). 
 
A reduction in AMP incorporation onto the tRNAAsp-NCC transcript was seen with the E43Δ variant as 
compared to the native enzyme in end point assays (Fig. 3-7).  At the highest enzyme amount tested 
(~10 ng), the E43Δ variant showed four-fold less product formation as compared to the native enzyme.  
Much like the R99W variant, this suggests that the ability to bind or incorporate AMP was affected.  To 
determine if the reduced ability to incorporate AMP was also seen for CMP incorporation, C-addition to 
the tRNAAsp-NC (Fig. 3-8) and tRNAAsp-N transcripts (Fig. 3-9) was assayed.  Using the tRNAAsp-NC 
transcript at ~10 ng of enzyme, the E43Δ variant showed 1.5-fold less incorporation of the second C as 
compared to the native enzyme (Fig. 3-8), however, with the tRNAAsp-N transcript at the same enzyme 
amount, higher incorporation of the first and second C’s by this variant was observed especially with 
respect to incorporation of the second C (which showed product formation three-fold higher with the 
variant than the native enzyme) (Fig. 3-9).  When both ATP and CTP were incubated with the tRNAAsp-N 
transcript, no substantial changes were seen for CMP incorporation at either of the expected positions 
on the transcript, however, a decrease in AMP incorporation was evident at the terminal position (Fig. 3-
10).  Therefore, like the R99W variant, these results suggest that the E43Δ variant may be defective in 
AMP but not CMP incorporation and so kinetic assays were performed in order to gauge the extent of 
impairment. 
 
4.2.5 No Change in KM,Apparent for Substrate Binding 
Regarding substrate affinities, the KM,Apparent values for ATP, CTP and tRNA
Asp-NCC binding to the E43Δ 
variant were all within three-fold of those of the native enzyme (Tables 3-1 to 3-3), suggesting that 
substrate binding is not affected by the loss of E43.  These data are consistent with the yeast R64W 
variant which also showed only small changes in these values (Rahman 2017).  Likewise, in most cases 
the previously characterized human variants showed KM,Apparent values that differed by at most two-fold 
as compared to the native human enzyme (Leibovitch et al. 2018, 2019).  So the data presented here 
agree well with what had been seen previously and suggest that there are no changes in substrate 
binding in the E43Δ variant that are linked to the disease phenotype.  We therefore looked at catalytic 





4.2.6 Different ATP and CTP Catalysis 
With respect to AMP incorporation into the tRNAAsp-NCC transcript, the calculated kcat of the E43Δ 
variant was between 16% and 30% of that of the native enzyme depending on which substrate was 
varied (Tables 3-1, 3-3).  When incorporating CMP into the tRNAAsp-NC transcript, the calculated kcat of 
the E43Δ variant actually was 120% that of the native enzyme (Table 3-2).  These values are in good 
agreement with what we have seen previously for the yeast R64W variant where the turnover number 
with varying CTP concentration decreased by a small amount (~25%) (Rahman 2017), and for the 
previously characterized human variants (Leibovitch et al. 2018) which showed values within 30% above 
or below that of the native enzyme, with the exception of the more C-terminal I326T variant for which 
the kcat dropped approximately six-fold (Leibovitch et al. 2019).  This suggests that, in terms of 
nucleotide incorporation kinetics, what is happening in the E43Δ variant is more similar to what is 
happening in the other N-terminal variants than in the C-terminal variant.  This again seems reasonable, 
given the biophysical data, suggesting that there are no major changes in the structure of the protein 
(Sections 4.2.1 to 4.2.3). 
 
4.2.7 Potential Contributions of Motif A, the Disordered and Flexible Loops, and Motif C 
As the C-terminus of α-helix 2 is separated by only three amino acids from the N-terminus of β-strand 1, 
which in turn constitutes the beginning of motif A (Fig. 3-16), the deletion of E43 may lead to the 
destabilization of α-helix 2 and the propagation of this destabilization that primarily affects motif A.  
Motif A, the most N-terminal element of the Class II tRNA-NT, is located in the head domain (Figs. 1-5, 3-
16) and contains two highly conserved catalytic carboxylates (DxD) (Yue et al. 1996).  Polymerization via 
AMP or CMP incorporation onto the 3’-end of the tRNA normally occurs by a two-metal ion binding 
mechanism which was first described for DNA polymerases (Steitz et al. 1994; Steitz 1998).  The two 
carboxylates bind and coordinate two Mg2+ ions at the catalytic core such that the first Mg2+ ion 
deprotonates the 3’-OH of the ribose of the terminal nucleotide of the tRNA.  This initiates a nucleophilic 
attack by the 3’-O- at the α-phosphate of the incoming ATP or CTP.  The second Mg2+ ion stabilizes the 
triphosphate moiety of ATP or CTP and promotes the release of the pyrophosphate group following the 
attack.  Both metal ions also stabilize the transition state intermediate.  Given the roles of these residues 
in the chemistry of the reaction, one would expect changes in their organization to alter kcat and not 
KM,Apparent.  However, here we see only small changes in either of these parameters, suggesting that the 
E43Δ variant does not alter the structure of motif A to affect the role of ATP or CTP in the reaction.  
Interestingly, the greatest drop in kcat (to approximately 16% of native) was seen when the ATP 
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concentration was held constant and the tRNAAsp-NCC concentration was varied.  This may suggest that 
alterations in structure at motif A are not manifested with respect to ATP or CTP, but with respect to the 
tRNA transcript.  Nonetheless, in silico protein-folding and subsequent in silico docking to tRNAAsp-NCCA 
revealed an increased distance between the two aspartates of motif A and the conserved R197 residue 
of motif D in the E43Δ variant as compared to that of the native enzyme (Fig. 3-17).  Assuming that the 
snapshot of the structures represents the A-adding reaction, this change may reflect an alteration of 
conformation of the nucleotide binding pocket due to the displacement of the R197 contact point for 
ATP away from the two carboxylates, such that the bound ATP is pulled away from motif A resulting in a 
decrease in turnover. 
 
In the structure of TRNT1, E43 is located in the head domain of TRNT1 which contains not only motif A, 
but also the disordered loop and the flexible loop (Fig. 3-16) described previously in Section 4.1.5 for the 
R99W variant.  It is possible that the deletion of E43 does not alter motif A, but may disrupt the function 
of the disordered loop or the flexible loop.  Similar to what we have proposed for the R99W variant, the 
deletion of E43 may disrupt the function of the flexible loop near E43 (Fig. 3-16) such that residues R126 
and/or T131 in the flexible loop (Fig. 3-18 D-F) are unable to induce the transition of the nucleotide 
binding pocket toward an ATP specificity.  It is equally likely that the E43 deletion initiates conformation 
changes (perhaps through disruption of a hydrogen bonding network) that displace residues D132, G133 
and/or R134 in the flexible loop (Fig. 3-18 D-F) resulting in the inability of the flexible loop to induce 
toggling of the nucleotide binding pocket toward an ATP specificity.  In contrast to the R99W variant, the 
latter effect in the E43Δ variant involving displacement of R134 is conceivable, since the kcat with varying 
tRNAAsp-NCC concentration showed a six-fold reduction (Table 3-3) and the kcat with varying ATP 
concentration of the R134A variant showed a 77-fold reduction (Hoffmeier et al. 2010), while the 
change in KM,Apparent for ATP binding for either variant was minimal to none (Table 3-1) (Hoffmeier et al. 
2010). 
 
In addition, in the yeast R64W variant, functional alteration of the flexible loop has been suggested by 
Rahman (2017) to occur if the hydrogen bonding network between residues R64 and A85, on adjacent β-
strands in the β-sheet of yeast tRNA-NT, is disrupted.  Residue A85 has been proposed to be normally in 
direct contact with the flexible loop, and so Rahman (2017) has predicted that disruption of this bonding 
network to residue A85 would subsequently affect the flexible loop and alter its function.  As the R64W 
substitution showed only a slight increase in CTP affinity, Rahman (2017) has suggested that as a 
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hydrogen bonding network is maintained with A85 regardless of the residue involved, the flexible loop 
would retain its normal function of mediating the CTP-to-ATP specificity switch.  As residues R64 and 
A85 in the yeast enzyme are conserved in the human enzyme (homologous to residues R60 and A81, 
respectively), and assuming that the secondary and tertiary structures of the two β-strands of the yeast 
enzyme are similar enough to those of the human enzyme (the crystal structure of yeast tRNA-NT has 
not yet been solved), the involvement of this hydrogen bonding network may also apply in the case of 
the deletion of E43.  Upon closer inspection, the two hydrogen bonds formed between R60 and A81 in 
the human enzyme (Fig. 3-19A) appear to be preserved when E43 is deleted (Fig. 3-19B), and since there 
are no changes to the secondary (Fig. S3C) or tertiary structure (Fig. 3-6) of the E43Δ variant as 
compared to that of the native human enzyme, this is not surprising.  These observations support our 
model that much smaller structural perturbations, as determined by thermal denaturation (Fig. 3-5), are 
involved in altering different regions of the human enzyme upon deletion of E43 such that AMP 
incorporation is reduced and CMP incorporation is increased, and argue against a major structural 
change in the single β-sheet in the enzyme. 
 
The results we obtained with the E43Δ variant may reflect changes in motif C of TRNT1.  Due to the 
proximity of residue E43 to motif C (Fig. 3-16), one can imagine how deletion of E43 might disrupt its 
function.  Motif C, located between the head and neck domains, contains a sequence which is sparsely 
conserved in Class II tRNA-NTs (Dx(3,4)Gx(9)R, where x(n) represents any n number of consecutive amino 
acids; the sequence of TRNT1 is DYFNGYEDLKNKKVR), and acts as a spring element between the head 
and neck domains (Ernst et al. 2015) (Figs. 1-5, 3-16).  Although it makes no contact with tRNA or 
nucleotides, motif C has been demonstrated to modulate the overall flexibility of the enzyme by 
properly orienting the tRNA and nucleotides in the catalytic core.  This is accomplished by the stretching 
of motif C upon binding of tRNA to the body domain so that the catalytic core is adjusted through 
precise stages in order to accommodate the growing tRNA.  In the human enzyme, Ernst et al. (2015) 
have shown that replacement of residue D168, in the sequence context of DYFNG above, with an 
alanine in the sparsely conserved sequence compromised this stretching such that the resulting enzyme 
variant was unable to incorporate AMP efficiently.  This being the case, the KM values for ATP and tRNA 
remained unchanged, demonstrating a general independence of motif C from the binding of these two 
substrates; however kcat for this variant was reduced 15-fold relative to the native enzyme (Ernst et al. 
2015).  Moreover, D168 has an equally vital function as it promotes a helix-capping interaction (Aurora 
and Rose 1998; Makhatadze 2005) with an α-helix.  Located between β-strand 6 and α-helix 6 (H6), D168 
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hydrogen bonds with G172 and Y173 in order to stabilize the α-helical conformation of helix 6 and 
subsequently influence the spring function of motif C (Ernst et al. 2015).  Naturally, the replacement of 
this aspartate with alanine has been envisaged to disrupt this helix-capping interaction and displace this 
α-helix (Ernst et al. 2015).  Thus, given our kinetics data for the E43Δ variant, which showed a six-fold 
decrease in kcat in AMP incorporation with varying tRNA
Asp-NCC (Table 3-3) but little change in KM,Apparent 
for ATP or tRNAAsp-NCC binding (Tables 3-1 and 3-3, respectively), it is plausible that the deletion of E43 
may also effect a conformation change that displaces D168 in motif C (Fig. 3-20 A-C) with similar 
outcomes as that of the D168A substitution.  This also would demonstrate the independence of the 
deletion of E43 from ATP or tRNAAsp-NCC binding, but nevertheless would lead to reduced AMP 
incorporation.  Furthermore, as the spring function of motif C would be altered, multiple rounds of C-
addition may also result yielding the run-on transcription products (tRNAAsp-NC(4) and tRNA
Asp-NC(5)) 
observed (Fig. 3-11 A, B). 
 
4.2.8 Augmented CMP Incorporation and Run-On Transcription 
As described above, if the ability of motif C to function as a spring is compromised, we may see multiple 
rounds of CMP incorporation.  To further explore the phenomenon of run-on transcription, additional 
activity assays were performed using the tRNAAsp-N and tRNAAsp-NC transcripts with higher enzyme 
amounts.  Under these conditions, we discovered that in addition to being more efficient at 
incorporating CMP into the penultimate and antepenultimate positions of the tRNA transcripts than was 
the native enzyme, the E43Δ variant also generated run-on transcription products of both the tRNAAsp-
NC (Fig. 3-11A) and tRNAAsp-N (Fig. 3-11B) transcripts more efficiently than did the native enzyme.  In 
fact, while the native enzyme seemed able to generate some tRNAAsp-NCCC run-on products under these 
conditions, the variant enzyme efficiently generated tRNAAsp-NC(4) (Fig. 3-11A) and tRNA
Asp-NC(5) (Fig. 3-
11B) run-on products. 
 
When the tRNAAsp-N transcript was used in the presence of both CTP and ATP (Fig. 3-11C), extension was 
limited to three nucleotides suggesting that competition between ATP and CTP occurs at the third 
position 3’ to the discriminator base, and that if AMP is incorporated (tRNAAsp-NCCA) extension is 
terminated and the final transcript product is released, but if CMP is incorporated (tRNAAsp-NCCC) C-
addition can continue.  Nevertheless, the ability of the E43Δ variant to incorporate CMP still far exceeds 




Perhaps in the E43Δ variant, the nucleotide binding pocket as defined by motif D or the flexible loop that 
plays a role in the conversion from CTP binding to ATP binding is rearranged in such a way that incoming 
CTP is much more readily accommodated by the E43Δ variant than it is by the native enzyme, due to the 
increase in affinity (Table 3-2).  This seems unlikely, given that the difference in the KM,Apparent values for 
CTP in the native and variant proteins differs by only about three-fold.  However, if we consider 
KM,Apparent values for both ATP and CTP, there is an almost 10-fold difference between them as the 
KM,Apparent value for ATP increases by three-fold as compared to the native enzyme.  However, when ATP 
is added to the reaction, run-on transcription is dramatically reduced (Fig. 3-11), suggesting that ATP can 
bind efficiently and once incorporated into tRNA terminates transcription. 
 
4.2.9 The E43Δ Variant Is Associated With Retinitis Pigmentosa and Erythrocyte-Linked Phenotypes 
Much like the R99W variant, the phenotypes associated with the E43 deletion are mild compared to 
those associated with other reported mutations (Table 1-1).  In fact, the only symptoms manifested in 
the one male patient reported to date are retinitis pigmentosa with erythrocytic microcytosis and 
anisocytosis with mild anemia (DeLuca et al. 2016) – a far cry from much more severe manifestations 
such as SIFD or B-cell immunodeficiency.  As described in Section 4.2.1, a minor decrease in thermal 
stability of this variant (Fig. 3-5) is likely to account for its decrease in abundance in dermal fibroblasts 
and iPSC-derived retinal organoids particular to this patient, relative to native protein levels in healthy 
control patients, and to contribute to the retinitis pigmentosa phenotype (DeLuca et al. 2016; Sharma et 
al. 2017).  Another aspect of the E43Δ variant is the three-fold decrease in the affinity for ATP (373.02 ± 
127.3 µM) that it shows relative to the native enzyme (124.31 ± 39.3 µM) (Table 3-1) – though the 
intracellular ATP concentrations of most cells in the human body are at least 1 mM, those of human 
lymphocytes have been reported to be as low as 390 or 463 µM (de Korte et al. 1985; Pagani et al. 
1991).  This suggests that the reduced affinity for ATP exhibited by this variant may be relevant in 
human lymphocytes.  This is interesting as there is no clinical evidence of any aberration in this cell type 
in the patient, yet red blood cells are more affected by this variant (e.g., microcytosis, anisocytosis and 
anemia) (DeLuca et al. 2016).  The intracellular ATP concentration in human red blood cells is known to 
be at least 1.5 mM (Torrance and Whittaker 1979; de Korte et al. 1985; Werner et al. 1987), and so the 
altered ATP affinity cannot be the cause of these reported red blood cell-linked pathologies. 
 
Considering all our data, we surmise that patients harboring the E43Δ variant are most likely sick due to 
the combination of a minor decrease in structural stability which may account for the red blood cell-
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linked pathologies, inefficient AMP incorporation arising from decreased affinity for ATP and a reduction 
in turnover number with respect to varying tRNAAsp-NCC concentrations, relative to the parameters of 
the native enzyme.  Regarding the red blood cell abnormalities, it has been proposed that this mutation 
might trigger an imbalanced synthesis of alpha or beta globin chains in hematopoietic cells (DeLuca et al. 
2016) and also adversely affect iron utilization (Taher et al. 2013). 
 
Because retinitis pigmentosa is characterized by the gradual degeneration of photoreceptor cells of the 
outer neural retina (DeLuca et al. 2016) and photoreceptor cells typically regenerate ~10% of their outer 
segments daily (Wangsa-Wirawan 2003), the function of which is photon detection, it is not surprising 
that one or more of these aberrations in TRNT1 structure or function could selectively and adversely 
affect the function of this cell type.  Indeed, as photoreceptor cells are highly metabolically active, a very 
high demand for protein synthesis is continually required and so any perturbation in this process would 
likely result in a dramatic change in phenotype.  Furthermore, Sharma et al. (2017) have demonstrated 
that the iPSC-derived retinal organoids harboring the E43Δ variant were deficient in autophagy and 
possessed high levels of oxidative stress, thought to be a major cause of photoreceptor cell injury and 
death.  Ultimately, as the E43 deletion only mildly compromises TRNT1, it stands to reason that these 
disease manifestations are non-life threatening and are also limited in scope and severity.  One caveat 
however is the recognition that the other allele of the patient, c.1246A[6] (DeLuca et al. 2016), may very 
well play an equally important role, if not a stronger one, in the development of these phenotypes, and 
so this work represents at best a partial study of the link between TRNT1 variant characteristics and 
disease manifestation.  To this end, work to define the biophysical and biochemical features of the A[6] 
variant is ongoing. 
 
4.3 A[8] Variant 
Although we were unable to characterize the A[6] variant, we did characterize the A[8] variant which 
like the A[6] variant results from a frame shift in the TRNT1 open reading frame, whereby an adenosine  
is deleted (A[6]) or inserted (A[8]) into a stretch of seven adenosine residues beginning at nucleotide 
1246 of the open reading frame.  These two variants yield proteins with their C-terminal amino acids 
replaced by others (DeLuca et al. 2016) (Table 4-1), which correspond to the most C-terminal mutations 





Table 4-1: Carboxy-Terminal Sequences of Native and c.1246A Frame Shift Variants 
Variant Amino acid sequence 
Native LREQWKKSGYQMEKDELLSYIKKT 
c.1246A[6] LREQWKKVVTKWKKMNF  
c.1246A[8] LREQWKKKWLPNGKR  
 
Note: The first amino acid change resulting from the frame shift is highlighted in green, positively 
charged amino acids are shown in red and negatively charged amino acids are shown in blue. 
 
The extra nucleotide in the A[8] variant results in a change in the primary sequence of the protein such 
that the most C-terminal α-helix of the protein (Fig. 1-6) is replaced by a short disordered region (Fig. 3-
21) such that the overall charge on this region of the protein changes from zero to +3 (Table 4-1) and the 
overall molecular mass of the protein is reduced by approximately 1 kDa. 
 
4.3.1 Increased Dimerization and Amount of Higher Molecular Weight Species 
As expected, SDS-PAGE denaturing gel electrophoresis showed no real difference in apparent mass 
between the native and A[8] monomers (Fig. 3-1).  Since the ability of TRNT1 to dimerize reflects the 
organization of the C-terminal body and tail domains of TRNT1 (Leibovitch et al. 2019), we tested for in 
vitro dimerization of the A[8] variant.  Like the native enzyme and most of the other variant proteins, 
but not the I326T variant (Leibovitch et al. 2019), the A[8] variant showed a covalent dimerization 
product on electrophoresis in the absence of reducing agent (Fig. 3-2).  In fact, under these conditions 
the A[8] variant actually showed a greater amount of dimer than did any of the other proteins tested 
(Fig. 3-2).  We previously have argued that the loss of covalent dimer in the I326T variant is linked to a 
change in the higher order structure of the monomer (Leibovitch et al. 2019), so perhaps an increase in 
the amount of covalent dimer also reflects a change in the structure of the protein.  That something has 
changed in the structure of the A[8] variant also may be reflected in non-denaturing gel electrophoresis, 
where a relative increase in the amount of high molecular weight species as compared to the native 
enzyme and the E43Δ and R99W variants is seen (Fig. 3-3).  To address the possibility that the higher 
order structure of the protein has changed, we used fluorescence and CD spectroscopies to look for 
changes in tertiary and secondary structure, respectively. 
 
4.3.2 No Change in Tertiary or Secondary Structure 
The mature native TRNT1 contains four tryptophan residues: W144, W239, W381 and W415; one in the 
region between conserved motifs A and B in the head domain of the protein (discussed previously in the 
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context of R99), one in the highly conserved motif E in the neck domain, and one each in the less well 
conserved body and tail domains of the protein, respectively.  In contrast, the A[8] variant contains five 
tryptophan residues with translation of the frame shift mutation resulting in an altered protein 
sequence and the introduction of the fifth tryptophan (W419) near W415 (Table 4-1).  Given this, 
fluorescence spectroscopy (upon excitation of tryptophan residues at 295 nm) was used to determine if 
any changes in the tertiary structure of A[8] as compared to the native enzyme could be detected.  
Surprisingly, no change (within error) was observed in the wavelength of maximum fluorescence for the 
A[8] variant as compared to the native enzyme (Fig. 3-6).  This suggests not only that there is no major 
change in tertiary structure but also that the addition of a tryptophan residue in the variant shows no 
effect on fluorescence.  The small red-shift (<3 nm) for the A[8] variant may reflect that either the new 
W419 or the existing W415 is more solvent-exposed as nine amino acids have been removed from the C-
terminus of the protein and the terminal α-helix has been lost.  The same approximately 3 nm red-shift 
in the wavelength of maximum fluorescence emission was also seen when all aromatic amino acids were 
excited at 280 nm (Fig. 3-6).  As excitation at this wavelength will account for all aromatic amino acids in 
the protein, this supports the idea that there is not a major change in tertiary structure in the A[8] 
variant as compared to the native enzyme. 
 
Similarly, no change in secondary structure of the A[8] variant was seen using CD spectroscopy (Fig. S3 
A-C).  This is not surprising given the overall primarily α-helical character of the protein (~60% α-helix) 
such that the loss of a single C-terminal α-helix resulted only in a small change in overall CD spectrum.   
 
So perhaps the increase in the amount of higher molecular weight species under non-denaturing 
conditions and the increase in the amount of covalent dimer seen do not reflect changes in the tertiary 
or secondary structure of the protein, but simply result from the loss of the C-terminal α-helix.  If one 
compares the predicted structure of the C-terminus of the A[8] variant (Fig. 3-21C) with the C-terminus 
of the native enzyme (Fig. 3-21D), one can see that with the loss of the C-terminal α-helix in the A[8] 
variant the antepenultimate and penultimate α-helices of the protein each has an additional surface 
exposed.  Perhaps exposing these surfaces allows monomers to associate in a different way such that 
the disulfide bond required for covalent dimerization can form more easily (Fig. 3-2) or that monomers 
may associate more easily under non-denaturing conditions (Fig. 3-3).  It is interesting that with the loss 
of the C-terminal helix (h22) some amino acids that would have been involved in interactions with this 
helix are now surface-exposed (Fig. 3-22).  In the A[8] variant, the new C-terminal helix (h21) now has 
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surface-exposed arginine and lysine residues in addition to a number of surface-exposed polar and 
hydrophobic residues (Fig. 3-22 B, D).  Also, the smaller helix (h20) N-terminal to this helix has a surface-
exposed aspartate along with two surface-exposed hydrophobic residues (Fig. 3-22 B, D).  It is possible 
that the newly exposed hydrophobic residues (L407 and L411 in the new C-terminal helix (h21) and I393 
and V396 in the smaller helix (h20)) (Fig. 3-22 B, D) may create part of a binding surface that facilitates 
association with another A[8] monomer and/or more easily promote disulfide bond formation at residue 
C373.  Moreover, the binding orientation of the tRNA to the A[8] variant also may be altered as the 
contact sites with helix h22 are removed and the newly exposed surfaces of helices h20 and h21 may 
interact with the tRNA (Figs. 3-21D, 3-22B, 3-22D). 
 
4.3.3 Minor Decrease in Structural Stability 
In terms of melting temperature, the change in Tm of this variant as compared to the native enzyme is 
much less than that seen with most of the other characterized human variants (5-7°C) (Leibovitch et al. 
2018, 2019), however, it is on par with that of the E43Δ variant, described above, as the latter variant 
also showed a decrease of Tm of ~2°C (Fig. 3-5).  Given that the E43Δ and A[8] changes are near the N- 
and C-terminus of the protein, respectively, perhaps it is not surprising that they have less of an effect 
on protein stability than do amino acid substitutions within the protein.  There is no difference in 
thermal stability whether the A[8] protein is pretreated with RNase or not, while for the native enzyme 
there is a ~2°C reduction in melting temperature after RNase treatment.  We previously attributed the 
increase in Tm in the presence of RNA to a contribution from bound tRNA as more energy is needed in 
the presence of the tRNA to denature both the tRNA and the protein.  This may suggest that in contrast 
to the native, R99W and E43Δ proteins, the A[8] variant binds tRNA less efficiently.  As with the E43Δ 
variant, the decrease in thermal stability associated with the A[8] variant is consistent with the reduced 
variant protein levels seen in dermal fibroblasts of two patients with retinitis pigmentosa showing the 
compound heterozygous A[8]/c.609-26T>C genotype (Table 1-1) (DeLuca et al. 2016).  Moreover, A[8] 
variant protein levels were significantly reduced in iPSC-derived retinal organoids specific for these two 
patients (Sharma et al. 2017), suggesting that the stability of the protein in general may be reduced.  
Like the E43Δ variant, these reports suggest that the overall reduced stability of the A[8] variant 






4.3.4 Major Decrease in tRNA Binding and Role of the Tail Domain 
If we use the A280:A260 ratio as an indicator of tRNA association with the variant during purification, we 
see that there is essentially no change in the A280:A260 ratio for the variant before or after RNase 
treatment (Fig. 3-4), while the native, R99W and E43Δ variants show at least a two-fold difference 
before and after RNAse treatment.  This supports the hypothesis that tRNA binds less efficiently to the 
A[8] variant, which has a C-terminal change in the protein’s primary structure, as compared to the 
native enzyme and the other variants with amino acid substitutions that are more N-terminal.  That a C-
terminal alteration in the protein’s primary structure should affect tRNA binding is not surprising. 
  
Available crystal structures and co-crystal structures of tRNA-NT enzymes with bound tRNA revealed 
that the body and tail domains of the protein are important for tRNA binding (Li et al. 2002; Xiong et al. 
2003; Tomita et al. 2004; Xiong and Steitz 2004; Yamashita and Tomita 2016).  These interactions are 
with the sugar-phosphate backbone of the tRNA substrate and most prominently with the D and TΨC 
arms found together in the tertiary structure of tRNA (Fig. 1-1).  Analysis of the structures of the regions 
of different tRNA-NTs that interact with the tRNA substrates revealed similar surface electrostatic 
potentials, shapes and sizes (Xiong et al. 2003; Xiong and Steitz 2004), suggesting that these domains 
play key roles in enzyme activity.  The most recent crystal structure of Thermotoga maritima tRNA-NT 
complexed with tRNA (bearing a complete CCA sequence) revealed direct interaction between the tail 
domain of the enzyme and the phosphate backbone of the tRNA (Yamashita and Tomita 2016), showing 
that this region of the protein anchors the tRNA to prevent it from being dislodged during the course of 
the reaction, as first proposed by Toh et al. (2009).  Yamashita and Tomita (2016) compared the crystal 
structures of Thermotoga maritima tRNA-NT with and without a bound tRNA substrate and noted that 
the tail of the enzyme moves around the tRNA to lock it in position.  They also identified specific lysine, 
glycine and asparagine residues that generate an arm-like element responsible for anchoring the tRNA 
in place. 
 
It seems reasonable to assume that a similar type of mechanism for tRNA positioning exists in other 
tRNA-NTs.  In fact, more than 40 years ago, Zhu and Deutscher (cited in Zhu and Deutscher (1987)) first 
indicated that an E. coli tRNA-NT lacking its 21 C-terminal amino acids showed no activity.  The more 
dramatic cleavage of 124 C-terminal amino acids from the Drosophila tRNA-NT reduced, but did not 
eliminate, its activity (Yang 2008).  More recently, we showed that simply converting the C-terminal 
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KAKRQRIE sequence of the 605-residue Arabidopsis thaliana tRNA-NT to EAEEQEIE resulted in reduced 
tRNA binding (three-fold increase in KD) and a reduction in enzyme activity (kcat decreased by 
approximately 40%) (Leibovitch et al. 2013).  Moreover, simply removing these nine amino acids 
resulted in a three-fold decrease in KD and a 60% drop in kcat as compared to the native enzyme 
(Leibovitch et al. 2013).  As the tail domain of tRNA-NT has been implicated in tRNA binding and enzyme 
activity, we set out to perform a more detailed enzymatic analysis of the A[8] variant. 
 
4.3.5 Kinetic Analysis and Possible Mechanisms of TRNT1 Alteration 
With all combinations of tRNA transcripts (tRNAAsp-N, tRNAAsp-NC or tRNAAsp-NCC) and nucleotides (ATP, 
CTP, or ATP and CTP), the A[8] variant showed the lowest level of NTP incorporation in end point assays 
of the three variants tested (Figs. 3-7 to 3-10).  As these assays cannot distinguish between the role of 
substrate binding or catalysis in the reduced activities seen, we performed more detailed kinetic 
analyses. 
 
These more detailed kinetic analyses revealed no real differences (all within a factor of two) in KM,Apparent 
for ATP, CTP (with a large experimental error) or tRNAAsp-NCC binding (Tables 3-1 to 3-3), however, an 
80- or 10-fold increase in KM,Apparent was seen for the tRNA
Asp-NC transcript (Table 3-4).  In contrast, 
nearly the opposite was observed when turnover numbers were calculated for these reactions.  The 
turnover number (kcat) for the addition of AMP to the tRNA
Asp-NCC transcript was only 3-10% of that of 
the native enzyme, depending on whether ATP (Table 3-1) or tRNAAsp-NCC (Table 3-3) concentrations 
were varied, while the kcat for the addition of CMP to the tRNA
Asp-NC transcript remained within three-
fold of that of the native enzyme, whether CTP (Table 3-2) or tRNAAsp-NC (Table 3-4) were varied.  This 
suggests that the changes at the C-terminus of the A[8] variant affect A- and C-additions differently.  
Similar decreases in kcat were seen when the 10 (decreased five-fold) or 33 (decreased eight-fold) C-
terminal amino acids were removed from TRNT1, although those deletions affected the KM,Apparent values 
for ATP and CTP differently (Leibovitch M., personal communication). 
 
Given the results of our CD and fluorescence spectroscopy studies, which suggest no major changes in 
the secondary (Fig. S3) or tertiary (Fig. 3-6) structure of the protein, a lack of a change in KM,Apparent for 
ATP or CTP binding mediated by amino acids in the head and neck domains of the enzyme was as 
expected, given that the A[8] variant results in amino acid substitutions in the C-terminus far from the 
active site (Fig. 1-6).  Likewise, an 80- or 10-fold increase in KM,Apparent for the tRNA
Asp-NC transcript also 
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was not unexpected as the tail domains of tRNA-NTs have been shown to be involved in tRNA binding 
(Shi et al. 1998; Yue et al. 1998; Tomita et al. 2004; Betat et al. 2004; Toh et al. 2009; Kuhn et al. 2015) 
and we saw a decrease in the amount of tRNA associated with the A[8] variant as compared to the 
native enzyme (Fig. 3-4) and an increase in higher molecular weight species, suggesting a change in 
organization of the C-terminus of the protein, as first proposed for the I326T variant (Leibovitch et al. 
2019).  What is more interesting is that this change in KM,Apparent was not seen for the tRNA
Asp-NCC 
transcript, yet AMP was incorporated into this transcript much less efficiently than was CMP into the 
tRNAAsp-NC transcript. 
 
4.3.5.1 Context of tRNA Binding and Orientation for CCA Addition 
Given the size of TRNT1 (~48 kDa) and that of the tRNAAsp-NC or -NCC transcript (~24 kDa), it is 
reasonable that multiple sites are involved in interactions with the tRNA (Betat et al. 2004; Yamashita et 
al. 2014; Kuhn et al. 2015; Yamashita and Tomita 2016).  Changes in these interactions could lead to 
altered tRNA binding or orientation on the enzyme, which may affect different kinetic parameters.  
Previously, in the context of the I326T substitution in the body of TRNT1, we have argued that amino 
acid substitutions that modify the arrangement in space of the body domain of the protein may alter 
how tRNAs can bind and/or be presented as substrate, and therefore may affect enzyme activity in 
different ways (Leibovitch et al. 2019).  Here, we propose that the replacement of the 17 C-terminal 
amino acids of TRNT1 with eight different amino acids (such that the protein loses its terminal α-helix 
and gains an overall positive charge in this region) results both in a decrease in the ability of this enzyme 
to bind and hold tRNA and to orient this tRNA properly for catalysis to occur. 
 
Our earlier results with the Arabidopsis tRNA-NT (Leibovitch et al. 2013) have shown that if we 
substitute four negatively charged amino acids for positively charged amino acids within the last eight C-
terminal amino acids of this protein, a 40% reduction in AMP incorporation into a tRNAAsp-NCC transcript 
is observed.  In contrast, if we simply remove nine C-terminal amino acids, a 60% reduction in enzyme 
activity results (Leibovitch et al. 2013).  In both cases, there was no real effect on KM,Apparent (Table 1 in 
Leibovitch et al. (2013)).  However, the KD’s were changed by approximately 10-fold when these two 
variants were compared, i.e., stronger binding was evident in the deletion variant, while weaker binding 
was seen in the charge variant.  In this case, we hypothesized that reducing the positive charge on this 
region of the protein reduced the potential for electrostatic interactions between the enzyme and the 
sugar-phosphate backbone of the tRNA substrate in the tail region of the protein such that binding was 
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less efficient.  In the case of the A[8] variant discussed here, we retain three positively charged residues 
(and lose three negatively charged residues), but the relative positioning of the positive charges is 
altered as the variant protein is predicted to lose its secondary structural character in this region (Table 
4-1).  So, although the overall positive charge in this region of the protein is increased in the A[8] variant, 
we see a loss of tRNA associated with the enzyme (Fig. 3-4).  This apparent reduced tRNA binding is 
reflected in the increased KM,Apparent for the tRNA
Asp-NC transcript (Table 3-4), but not the tRNAAsp-NCC 
transcript (Table 3-3). 
 
This suggests that, as with the Arabidopsis enzyme, this region of the protein is most important in 
binding tRNA prior to nucleotide incorporation and that as the tRNA is extended by cytidine, cytidine 
and adenosine, this region of the protein becomes less important in tRNA binding.  However, it still must 
play a role in orienting the extending tRNA substrate appropriately for catalysis to continue.  Fewer 
correct hydrogen-bonding or electrostatic interactions between the enzyme and the tRNA may alter this 
orientation.  When the tRNA is modeled on the native enzyme or the A[8] variant (Fig. 3-21), a large 
difference in rotational position on the proteins is predicted (Fig. 3-21A).  So while modeling suggests 
that if the tRNA binds to the A[8] variant, then its orientation is different from that of tRNA bound to the 
native enzyme.  This model is supported by the observations that the KM,Apparent’s for ATP, CTP and 
tRNAAsp-NCC are close to those of the native enzyme (Tables 3-1 to 3-3), while the kcat value for AMP 
incorporation into the tRNAAsp-NCC transcript is reduced dramatically (Tables 3-1 and 3-3).  
 
We propose that, in the native enzyme, the terminal α-helix (EKDELLSYIKKT) shows a positively charged 
face that can be involved in tRNA binding and organization.  When that sequence is lost, as in the 10- or 
33-amino acid deletion variants, or truncated by nine amino acids and replaced by the unstructured 
KWLPNGKR sequence of the A[8] variant, tRNA binding efficiency is reduced due to the loss of the 
positive charges and the α-helical structural motif.  Furthermore, once the tRNA substrate is bound, this 
sequence may be responsible for anchoring the tRNA in position for subsequent cycles of C-, C- and A-
addition.  The separate roles that this sequence may play in tRNA binding and orientation may be 
reflected by the rearrangements that occur in the substrate and the conformational changes that the 
enzyme must undergo during the course of the reaction (Tomita et al. 2006; Toh et al. 2009; Yamashita 





Specifically, the tRNA-NT nucleotide binding pocket has different conformations for the incorporation of 
CMP and for AMP, and so has to undergo a conformational change after C-addition to allow for A-
addition (Tomita et al. 2004; Toh et al. 2009; Yamashita et al. 2014; Ernst et al. 2015; Yamashita and 
Tomita 2016).  We argue, due to the changes in the C-terminus of the A[8] variant, that once tRNA is 
bound, it is not oriented appropriately for C- and A-addition (approximated in Fig. 3-21A).  Specifically, 
once the enzyme has undergone the conformational change from CTP binding to ATP binding, the active 
site is arranged to bind ATP efficiently (as evidenced by the KM,Apparent value close to that of the native 
enzyme), but the tRNA substrate is not appropriately oriented for the chemistry to happen (as 
evidenced by the drop in kcat).  This may result from a change in where the tRNA is bound on the 
enzyme, as the C-terminal sequences have been changed, or from the fact that the tRNA is not anchored 
strongly enough at the active site for the chemistry to happen (approximated in Fig. 3-21A).  We saw 
similar characteristics in the I326T variant that we characterized previously, and Ernst et al. (2015) also 
proposed a similar explanation for a mutation in the neck domain of the protein, i.e., although both 
substrates were bound to the enzyme, the distance and/or orientation of the substrates was altered 
such that the required nucleophilic attack did not occur efficiently.  While these authors argue that this 
altered arrangement results from an amino acid substitution in the head and neck domain, we suggest 
that given the size of the tRNA substrate, the same type of altered organization of substrates could 
result from a modification in the C-terminal tail portion of the protein, reflecting primarily the 
positioning of the tRNA substrate. 
  
4.3.5.2 Similar C-Terminal Variants 
As the frame shift mutation altering the sequence and structure of TRNT1 starts at amino acid 418, it is 
interesting that there is a single point mutation that results in a protein with a K416E substitution in this 
region of the protein, which also results in SIFD (Chakraborty et al. 2014).  Leibovitch (2016) showed that 
in the K416E variant, there was a small (less than four-fold) change in KM,Apparent for ATP or CTP (as we see 
here for the A[8] variant), but a seven-fold increase in KM,Apparent for tRNA
Asp-NCC (in contrast to the small 
change that we see here).  Moreover, in terms of changes in kcat, AMP addition to the tRNA
Asp-NCC 
transcript was only about 62% of that of the native enzyme as compared to the 10- to 30-fold reduction 
that we saw with the A[8] variant.  Furthermore, the K416E variant showed an approximately 125-fold 
decrease in affinity for tRNA (Leibovitch 2016), which is consistent with the reduced tRNA binding that 
we saw with the A[8] variant (Fig. 3-4).  Taken together, these data suggest that the K416E substitution, 
on its own, can reduce the binding of the tRNA substrate, but that once the tRNA is bound, the reaction 
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parameters that we measured were more similar to the native enzyme than to the more dramatic A[8] 
variant.  This may suggest that the K416E substitution more dramatically affects tRNA binding than 
orientation during catalysis, although there is some effect on catalysis.  One can imagine that K416 plays 
an early role in interacting directly with the negatively charged sugar-phosphate backbone of the tRNA 
during binding, or that this amino acid substitution alters the structure of this region of TRNT1 such that 
tRNA binding is reduced. 
 
It also would be interesting to characterize the A[6] variant (DeLuca et al. 2016), which like the A[8] 
variant represents a frame shift mutation, but in this case resulting from the loss of a single adenine 
residue.  This variant again begins at position 418, but results in the sequence VVTKWKKMNF such that 
the variant protein is seven amino acids shorter than the native enzyme but maintains three positively 
charged amino acids. 
 
4.3.6 The A[8] Variant Is Associated With Systemic Phenotypes 
The combined reduced tRNAAsp-NC binding and A-adding activity that we saw in vitro may contribute to 
the phenotypes observed in the four human patients harboring the A[8] frame shift.  The two brothers 
with the compound heterozygous A[8]/c.609-26T>C genotype exhibit a mild phenotype (Table 1-1), 
which is strikingly similar to that exhibited by the male patient with the compound heterozygous 
E43Δ/c.1246A[6] genotype (discussed in Section 4.2.9) (DeLuca et al. 2016).  In fact, all three of these 
patients display the same symptoms – retinitis pigmentosa with erythrocytic microcytosis and 
anisocytosis with mild anemia.  As in the case with the E43Δ variant (discussed in Section 4.2.9), a minor 
decrease in thermal stability of the A[8] variant (Fig. 3-5) may play a role in reduced protein levels in 
dermal fibroblasts and iPSC-derived retinal organoids particular to these two brothers and contribute to 
the retinitis pigmentosa phenotype (DeLuca et al. 2016; Sharma et al. 2017).  Coupled with the 
weakened tRNAAsp-NC binding and decreased A-adding activity, this altered stability may likewise induce 
in these retinal organoids high levels of oxidative stress, which generally are detrimental to 
photoreceptor cells (Sharma et al. 2017). 
 
Moreover, the combination of the changes that were seen in the in vitro experiments with respect to 
thermal stability, tRNA binding and turnover number may play a role in red blood cell-linked 
abnormalities.  These pathologies include microcytosis, anisocytosis and mild anemia exhibited by these 
two brothers (DeLuca et al. 2016), and sideroblastic anemia exhibited by the young child with the 
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compound heterozygous A[8]/I223T genotype (Chakraborty et al. 2014; Giannelou et al. 2018) and one 
patient with the compound heterozygous A[8]/K416E genotype (Giannelou et al. 2018) (Table 1-1).  As 
with the E43Δ deletion, the A[8] frame shift in these patients might lead to an imbalanced synthesis of 
alpha or beta globin chains in hematopoietic cells (DeLuca et al. 2016) and detrimentally affect iron 
utilization (Taher et al. 2013). 
 
Of course, one must also consider the partial LOF conferred by the other allele in each patient.  In the 
case of the two brothers (A[8]/c.609-26T>C genotype), the c.609-26T>C intronic point mutation is 
unlikely to drastically alter the TRNT1 protein, as DeLuca et al. (2016) have shown by Western blot 
analysis that potentially alternatively spliced transcripts would simply not reach the protein translation 
stage, and therefore the phenotype presented would likely be due to the overall reduced levels of 
TRNT1 and the properties of the A[8] variant.  This suggests that the effects of the A[8] variant, on their 
own, would not be severe enough to cause systemic and life-threatening conditions as the phenotypes 
exhibited by these two brothers are relatively mild (DeLuca et al. 2016).  This also suggests that the 
more dramatic phenotype seen in the A[8]/I223T genotype (Giannelou et al. 2018), including SIFD 
(Chakraborty et al. 2014), must be driven primarily by the I223T substitution.  Indeed, this makes sense 
as the I223T substitution has already been shown to be relatively severe from in vitro studies (Leibovitch 
et al. 2018).  In the case of the A[8]/K416E genotype, the K416E substitution would also be an important 
contributor to the clinical manifestations observed (Giannelou et al. 2018), as hypogammaglobulinemia 
and developmental delay are systemic and the K416E variant, like the A[8] variant, demonstrates poor 
tRNA binding and a low specificity constant (Leibovitch 2016) and so is inefficient in generating mature 













5.0 CONCLUSIONS AND FUTURE WORK 
 
In this work, we set out to perform in vitro biophysical and biochemical characterizations of mutational 
variants of TRNT1, the human tRNA nucleotidyltransferase (tRNA-NT), in order to understand better the 
roles of specific amino acids and related structures of this protein in the context of protein stability, 
structure and function and, by extension, TRNT1-linked pathogenesis.  The present work complements 
the studies of Leibovitch et al. (2018, 2019) by focusing on TRNT1 variants generated from the E43Δ 
deletion (DeLuca et al. 2016), R99W substitution (Aksentijevich et al. 2014; Hull et al. 2016; Frans et al. 
2017; Kumaki et al. 2019) and A[8] frame shift (Chakraborty et al. 2014; DeLuca et al. 2016; Giannelou et 
al. 2018) – mapping to different regions of the resulting protein. 
 
All three of these variants, regardless of type or location of modification, demonstrated major 
quantifiable decreases in AMP incorporation.  The R99W variant showed a decrease in AMP 
incorporation likely based on reduced kcat and decreased KM,Apparent for ATP binding (Sections 4.1.4 and 
4.1.5), but led to relatively mild phenotypes in patients who are homozygous for R99W (Hull et al. 2016; 
Frans et al. 2017) as compared to those in patients bearing other mutations (Table 1-1).  This suggests 
that the tremendous increase (~100-fold) in ATP binding to the R99W variant and lowered turnover 
number indicate that catalysis is compromised due to improper conformational changes either in the 
specificity switch toward ATP or in the catalysis of AMP incorporation itself.  The E43Δ variant also 
showed a similar decrease in AMP incorporation, but likely based primarily on an increased KM,Apparent for 
ATP (Sections 4.2.4 and 4.2.5).  This decreased affinity for ATP may have led to a phenotype confined 
primarily to the high-energy-requiring cells of the retina where ATP is used rapidly and continued 
protein synthesis is required, such that retinitis pigmentosa results (DeLuca et al. 2016; Sharma et al. 
2017).  Finally, the A[8] variant showed an almost 10-fold reduction in kcat for AMP incorporation 
(Section 4.3.5) and also at least a 10-fold increase in KM,Apparent for tRNA
Asp-NC binding (Section 4.3.5.1).  
The combination of the weakening of both of these kinetic parameters may explain why this variant 
shows more severe phenotypes (Chakraborty et al. 2014; Giannelou et al. 2018). 
 
In all three cases, effects on the incorporation of AMP seem to be the dominant factor leading to the 
phenotypes observed.  Effects on the incorporation of CMP are not as pronounced as those of AMP and, 
in the case of the E43Δ variant, CMP incorporation seems even more efficient than in the native enzyme.  
Moreover, no major changes in thermal stability (always ≤3oC) were seen in any of the variants (Sections 
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4.1.3, 4.2.1 and 4.3.3).  It is hence conceivable that as even small changes in the structure or stability of 
the R99W, E43Δ and A[8] variants are altered, different substructures, domains and motifs would be 
shifted in conformation such that AMP but not CMP incorporation is compromised.  This may be linked 
to the inability to alter the conformation of the enzyme during the switch from CMP to AMP 
incorporation (Sections 4.1.5, 4.2.7, 4.2.8 and 4.3.5.1).  Given the importance of ATP in the cell, it is not 
surprising that either a reduced ability to bind or to incorporate ATP would lead to a disease phenotype.   
 
The T154I, M158V, L166S, R190I, I223T and I326T variants all also showed decreased AMP incorporation 
onto various tRNA transcripts (Leibovitch et al. 2018, 2019).  For instance, the I326T variant showed a 
kcat that was nine-fold lower than that of the native enzyme for AMP incorporation onto the tRNA
Asp-
NCC transcript (Leibovitch et al. 2019), while the R190I variant showed reduced AMP incorporation onto 
a mitochondrial tRNASer(AGY) transcript as well as a mini-tRNA derivative from B. subtilis tRNAAsp 
(Leibovitch et al. 2018).  Again, this suggests the importance of reduced AMP incorporation in the 
context of a disease phenotype.  However, all of these variants showed a reduced thermal stability of 
≥~5-7°C from that of the native enzyme (Leibovitch et al. 2018, 2019), suggesting a greater role of 
reduced thermal stability in these variants.  It is intriguing that the R99W substitution near the active 
site shows a small decrease in thermal stability (<1°C), while all of the other active site substitutions 
characterized by Leibovitch et al. (2018, 2019) show the larger decrease in thermal stability.   
 
An important limitation in the interpretation of this work, at the level of phenotype, is that eight out of 
the 12 patients described exhibit a compound heterozygous genotype.  These are the R99W/D163V 
(Aksentijevich et al. 2014), R99W/R412X (Kumaki et al. 2019), E43Δ/A[6] (DeLuca et al. 2016), 
A[8]/c.609-26T>C (DeLuca et al. 2016), A[8]/I223T (Chakraborty et al. 2014; Giannelou et al. 2018) and 
A[8]/K416E (Giannelou et al. 2018) genotypes.  In the case of the patients with the A[8]/c.609-26T>C 
genotype, any alternatively spliced transcripts resulting from the c.609-26T>C intronic point mutation 
are likely removed from the protein translation process and only the A[8] frame shift mutation likely 
influences the phenotype (DeLuca et al. 2016) (Section 4.3.6).  In the cases of the patients with the 
A[8]/I223T and A[8]/K416E genotypes, the altered properties of the I223T and K416E variant proteins 
have been determined.  The I223T variant binds CTP less well (Leibovitch et al. 2018) and the K416E 
variant binds tRNA less well (Leibovitch 2016).  Therefore, an additive effect resulting from the 
combination of defects in the two partial LOF mutations in each of these patients may have led to the 
more severe phenotypes observed (Section 4.3.6). 
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Expressing each of these variant enzymes in Saccharomyces cerevisiae under the control of the native 
yeast CCA1 promoter allowed for growth of a strain expressing the E43Δ variant, but not the R99W and 
A[8] variants, suggesting that in vivo the effects of the latter variants are more dramatic (Hanic P., 
personal communication).  However, overexpression of these proteins from the ScTDH3 promoter 
ensuring a higher level of gene expression allowed for growth with the E43Δ and R99W variants, but not 
the A[8] variant, suggesting that in vivo the A[8] variant is the most severely altered.  This likely results 
from the combination of less efficient incorporation of AMP and reduced tRNA binding in this variant.  
These in vivo findings therefore support our claim that efficiency of AMP incorporation by these variants 
is a major criterion for cell survival, and that as the ability to incorporate AMP declines as in the case of 
the R99W, E43Δ and A[8] variant-expressing yeast strains, cell survival is adversely affected.   
 
In this work, our data suggest that displacements of key residues within certain structures or motifs of 
TRNT1 due to structural shifts led to functional aberrations of these structures or motifs – triggering the 
decline in the overall ability of the enzyme to incorporate AMP.  This is likely attributable to impairments 
of the disordered loop and the flexible loop for the R99W and E43Δ variants (Sections 4.1.5 and 4.2.7, 
respectively) and of motif C for the E43Δ variant (Section 4.2.7).  Furthermore, as the spring function of 
motif C is possibly altered following the deletion of residue E43, multiple rounds of C-addition may occur 
yielding run-on transcription products with up to five C residues added to the 3’-ends of tRNAs in our in 
vitro assays (Section 4.2.8).  We also suggest that the tail domain of the TRNT1 enzyme, in addition to 
binding tRNA prior to nucleotide incorporation, has a crucial role in orienting the extending tRNA so that 
all appropriate substrates are properly aligned at the active site of the enzyme for catalysis to occur 
(Section 4.3.5.1). 
 
Future work aimed at elucidating additional functions of the tail domain of TRNT1 and confirming the 
findings made here for the A[8] variant may include the characterization of the A[6] variant, which is 
also shortened and retains three positively charged amino acids near its C-terminus (Section 4.3.5.2).  It 
would be interesting to see if, for the A[6] variant, tRNA binding is similarly reduced or if catalytic 
properties are similar to those of the A[8] variant.  Binding studies of this variant and of the R99W, E43Δ 
and A[8] variants with tRNA, either through fluorescence quenching (Shan et al. 2008) or gel filtration 
chromatography (Leibovitch et al. 2019), would reveal KD values for tRNA and quantify tRNA binding 
affinity independent from that described by KM,Apparent values discussed in this work.  This would allow 
more comprehensive comparisons in terms of tRNA binding with other TRNT1 substitution variants 
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already characterized (Leibovitch 2016; Leibovitch et al. 2019), given the disconnect we have seen 
between KD and KM,Apparent values for other tRNA-NTs (Leibovitch et al. 2013, 2019; Leibovitch 2016). 
 
Sideroblastic anemia, characterized by the presence of ring sideroblasts (red blood cell precursors 
marked by granular deposition of unincorporated iron in mitochondria forming a ring around the 
nucleus), is a mitochondrial disorder seen in multiple patients (Chakraborty et al. 2014) (Table 1-1).  This 
disease likely results from reduced levels of functional TRNT1 in mitochondria leading to defects in 
mitochondrial protein synthesis.  However, reduced functional TRNT1 in mitochondria may result from 
reduced stability, activity or amounts of the protein.  In this work, the data from the characterized 
variants suggest reduced activity, but as yet we cannot exclude the possibility that there is actually less 
variant TRNT1 delivered to the mitochondrion.  Given that the A[8] variant results in sideroblastic 
anemia, perhaps the change in stability and/or other physicochemical properties of the A[8] variant 
trigger(s) an altered distribution of this variant with respect to mitochondria localization.  In addition, 
other disease phenotypes including sensorineural hearing loss associated with the R99W and A[8] 
mutations, and retinitis pigmentosa associated with the E43Δ mutation (Table 1-1), also involve tissues 
that have high energy demands and require efficient mitochondrial respiration.  Therefore, in vivo 
localization studies may provide insight into the possible changes in subcellular localization of these 
altered TRNT1 proteins in human cells (e.g., toward the cytosol, nucleus and/or mitochondria) in order 
to further place into context the biophysical and biochemical alterations of this essential enzyme.  
Indeed, Leibovitch et al. (2013) have shown that changes in stability in the body and tail domains of the 
Arabidopsis tRNA-NT, and not just the N-terminal transit peptide, influence the targeting of the tRNA-NT 
toward different organelles and a similar mechanism may be in place in human cells. 
 
The results of this work reveal that, as opposed to our initial hypothesis based on the biophysical and 
biochemical characterization of the existing human TRNT1 variants (Leibovitch 2016; Leibovitch et al. 
2018; Leibovitch et al. 2019), a change in thermal stability is not the primary defect leading to a disease 
phenotype in the E43Δ, R99W and A[8] variants.  Instead, these variants suggest a role in ATP binding 
and incorporation.  Even the A[8] variant, which as in other C-terminal variants (Leibovitch M., personal 
communication) showed reduced tRNA binding, also showed reduced AMP incorporation.  This suggests 
that mutations lead to different types of defects in TRNT1 (affecting structure and/or function) that 
result in disease phenotypes.  Given the absolute need for functional TRNT1, it will be interesting to see 
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how many different classes of partial LOF mutations will be discovered – in addition to those that alter 
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Figure S1: Densitometry Analysis of SDS-PAGE of Native and Variant TRNT1 Proteins 
 
Intensity peaks representing the protein species separated per gel lane by SDS-PAGE (Figure 3-1).  Each 
spectrum displays peaks from left to right in order of descending molecular weight.  (A) Native, (B) 











Figure S2: SDS-PAGE, Non-Reducing SDS-PAGE and Native PAGE of Native and Variant TRNT1 Proteins.  
Original gels include the A[6] variant (not discussed in this thesis). 
 
(A) SDS-PAGE – for legend, refer to Figure 3-1. 
(B) Non-reducing SDS-PAGE – for legend, refer to Figure 3-2. 




Figure S3: CD Spectra of Native and Variant TRNT1 Proteins 
 
Signal traces are displayed for native (black), R99W (blue), E43Δ (cyan) and A[8] (green).  Traces for 
RNase-treated and non-RNase-treated aliquots are displayed as solid lines and dashed lines, 
respectively.  For each trace, the number of experimental replicates is denoted in parentheses.  Each 
error bar above or below a data point represents one SEM.  All traces are representative of a mixed α-
helix/β-strand character. 
 
(A) Traces are shown with ellipticity (m°) as a function of absorption (nm).  These correspond to the raw 
data and reflect the unequal protein concentrations of the aliquots. 
(B) Traces are shown with mean residue ellipticity (MRW) (°•cm2•dmol-1•103) as a function of 
absorption (nm).  [θ]MRW = 100•θ / (C•N•L); where θ = ellipticity (m°), C = concentration (M), N = 
number of amino acids in the protein and L = cuvette pathlength (cm) = 0.2 cm (Kelly et al. 2005). 
(C) Traces are shown with ellipticity rescaled as arbitrary units (a.u.) as a function of absorption (nm).  




Figure S4: Thermal Denaturation Curves of Native and Variant TRNT1 Proteins 
 
Denaturation curves are displayed for native (black), R99W (blue), E43Δ (cyan) and A[8] (green).  Curves 
for RNase-treated and non-RNase-treated aliquots are displayed as solid lines and dashed lines, 
respectively.  For each curve and corresponding Tm, the number of experimental replicates is denoted in 
parentheses.  Each error bar above or below a Tm data point represents one SEM. 
 
(A) Curves are shown with ellipticity (m°) as a function of temperature (°C).  These correspond to the 
raw data and reflect the unequal protein concentrations of the aliquots. 
(B) Curves are shown with ellipticity rescaled as arbitrary units (a.u.) as a function of temperature (°C).  
Each trace is rescaled such that 20 °C corresponds to -20 a.u. 
(C) Curves are shown with fraction unfolded (F) as a function of temperature (°C).  F = (θ - θi) / (θf - θi); 
where θ = ellipticity (m°), θi = initial ellipticity (m°) at 20 °C and θf = final ellipticity (m°) at 54.5 °C 




Figure S5: Fluorescence Emission Spectra of Native and TRNT1 Variant Proteins (Non-RNase-Treated) 
 
Emission traces are displayed for non-RNase-treated aliquots of native (black), R99W (blue), E43Δ (cyan) 
and A[8] (green).  Traces from 280-nm and 295-nm excitations are displayed as solid lines and dashed 
lines, respectively.  For each trace and corresponding maximum, the number of experimental replicates 
is denoted in parentheses.  Each error bar above or below a maximum represents one SEM. 
 
(A) Traces are shown with intensity (arbitrary units, a.u.) as a function of emission (nm).  These 
correspond to the raw data and reflect the unequal protein concentrations of the aliquots. 
(B) Traces are shown with rescaled intensity (a.u.) as a function of emission (nm).  Each trace is rescaled 




Figure S6: Fluorescence Emission Spectra of Native and TRNT1 Variant Proteins (RNase-Treated) 
 
Emission traces are displayed for RNase-treated aliquots of native (black), R99W (blue), E43Δ (cyan) and 
A[8] (green).  Traces from 280-nm and 295-nm excitations are displayed as solid lines and dashed lines, 
respectively.  For each trace and corresponding maximum, the number of experimental replicates is 
denoted in parentheses.  Each error bar above or below a maximum represents one SEM. 
 
(A) Traces are shown with intensity (arbitrary units, a.u.) as a function of emission (nm).  These 
correspond to the raw data and reflect the unequal protein concentrations of the aliquots. 
(B) Traces are shown with rescaled intensity (a.u.) as a function of emission (nm).  Each trace is rescaled 




Figure S7: Sample Kinetic Assay Plots for Native TRNT1 Enzyme 
 
Displayed on the left-hand side are representative kinetic assay plots for native TRNT1 fitted to the 
Michaelis-Menten model using nonlinear regression via GraFit 7 (Leatherbarrow 2009).  Displayed on 
the right-hand side are Lineweaver-Burk plots corresponding to the former.  Each error bar above or 
below a data point represents one SEM. 
 
(A) Varying ATP and fixed tRNAAsp-NCC as substrates; 4.82 ng of enzyme per reaction. 
(B) Varying CTP and fixed tRNAAsp-NC as substrates; 1.83 ng of enzyme per reaction. 
(C) Varying tRNAAsp-NCC and fixed ATP as substrates; 0.23 ng of enzyme per reaction. 
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